

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, A61K 48/00	A1	(11) International Publication Number: WO 98/14573 (43) International Publication Date: 9 April 1998 (09.04.98)
(21) International Application Number: PCT/US97/17900 (22) International Filing Date: 30 September 1997 (30.09.97) (30) Priority Data: 60/027,128 30 September 1996 (30.09.96) US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). (72) Inventors: LUSTER, Andrew, D.; 24 Windmere Road, Welles- ley, MA 02181 (US). GARCIA-ZEPEDA, Eduardo; 271/2 Adrian Street, Somerville, MA 02143 (US). SARAFL, Mindy; 87 Sheridan Street #3, Jamaica Plains, MA 02130 (US). (74) Agent: BIEKER-BRADY, Kristina; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).		(81) Designated States: CA, CN, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: MCP-4 AND MCP-5: NOVEL CHEMOKINES (57) Abstract Substantially pure nucleic acid molecules encoding the monocyte chemotactic proteins MCP-4 and MCP-5. These molecules and the polypeptides they encode are useful in treating diseases or conditions that: (1) are exacerbated by a local immune response, (2) would benefit from a local immune response, or (3) are caused by infectious agents that gain entry to mammalian cells via the chemokine receptors bound by MCP-4 or MCP-5.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MCP-4 AND MCP-5: NOVEL CHEMOKINES

Background of the Invention

5 The invention relates to novel chemoattractants.

 Six different types of white blood cells (leukocytes) are typically found in the blood. These are neutrophils, eosinophils, basophils, monocytes, lymphocytes, and plasma cells. The neutrophils and monocytes are primarily responsible for attacking and destroying invading bacteria, viruses, and other harmful agents.

10 Neutrophils circulate within the bloodstream as mature, functional cells. Monocytes, however, circulate as immature cells that have a limited ability to fight infectious agents. It is only when monocytes are stimulated by chemotactic agents to move through the capillary wall into surrounding tissue that they become fully active. Once monocytes enter the tissues they begin to swell and many lysosomes and mitochondria appear in their cytoplasm. At this point, monocytes become
15 called macrophages, which are extremely effective phagocytes. Each macrophage can engulf as many as 100 bacterial cells, as well as large particles, including whole red blood cells, malarial parasites, and necrotic tissue.

 Chemokines are chemotactic cytokines that contribute to various immune
20 and inflammatory responses by regulating the movement of selected blood-borne leukocytes into the tissues (Baggiolini et al., Adv. Immunol. 55:97-179, 1994; Oppenheim et al., Ann. Rev. Immunol. 9:617-648, 1991). All known chemokines have been assigned to one of three families on the basis of the chromosomal location of the genes that encode them and on the motif formed by conserved
25 cysteine residues in the mature proteins. Two of these families, designated α and β , have many members, all of which have four conserved cysteine residues. The first two cysteines of α chemokines are separated by a single amino acid (CXC motif), and these proteins are encoded by genes clustered on human chromosome 4. In contrast, the first two cysteines of all β family chemokines are

-2-

adjacent to one another (CC motif), and these proteins are encoded by genes clustered on human chromosome 17.

Chemokines having the CXC motif (α chemokines) primarily affect neutrophils and lymphocytes, and they can modulate angiogenesis. Chemokines having the CC motif (β chemokines) affect monocytes, lymphocytes, eosinophils, and basophils with variable selectivity. In addition, certain chemokines in the α and β family can inhibit HIV replication in T cells and monocytes, respectively.

The third chemokine family currently has only one member: the T cell-specific chemoattractant, lymphotactin (Kelner et al., Science 266:1395-1399, 1994). The gene encoding lymphotactin is located on human chromosome 1, and the protein sequence contains only the second and fourth cysteines found in the α and β chemokine families (Kennedy et al., J. Immunol. 155:203-209, 1995).

The monocyte chemoattractant proteins (MCPs), which constitute a subfamily of the β chemokines described above, include the three human MCP proteins (MCP-1, MCP-2, and MCP-3). These proteins are ~65% identical, and all have Gln as their N-terminal amino acid (Van Damme et al., J. Exp. Med. 176:59-65, 1992; Yoshimura et al., J. Exp. Med. 169:1449-1459, 1989).

The chemokine eotaxin is also a β chemokine. It is related in sequence to the MCP proteins, but does not contain an amino-terminal Gln residue. Eotaxin appears to be unique among the chemokines in that it causes the selective infiltration of eosinophils when injected subcutaneously and when administered directly to the lungs of naive guinea pigs.

Five genes encoding human β chemokine receptors, referred to as CKR1 through CKR5, have been cloned. (Charo et al., Proc. Natl. Acad. Sci. USA 91:2752-2756, 1994; Combadiere et al., DNA and Cell Biol. 14:673-380, 1995; Combadiere et al., J. Leukocyte Biol. in press, 1996; Gao et al., J. Exp. Med. 177:1421-1427, 1993; Neote et al., Cell 72:415-425, 1993; Power et al., J. Biol. Chem. 270:19495-19500, 1995; Samson et al., Biochem. 35:3362-3367, 1996).

-3-

CKR2a and CKR2b are splice variants of the same gene. These receptors are not ubiquitously expressed: CKR1, CKR4, and CKR5 appear to be widely expressed on leukocytes, while expression of CKR2 and CKR3 is mainly restricted to monocytes and eosinophils, respectively.

5 Summary of the Invention

The invention features substantially pure nucleic acid molecules that encode MCP-4 and MCP-5, two novel members of the β -chemokine family. The invention also includes polypeptides encoded by these nucleic acid molecules.

10 The nucleic acid molecules may consist of genomic DNA, cDNA, or mRNA, and, due to the degenerate nature of the genetic code, may vary in sequence provided that the encoded polypeptides are MCP-4 or MCP-5, as shown, for example, in Figs. 1A and 1B, respectively.

15 Substantially pure MCP-4 and MCP-5 polypeptides, biologically active fragments of these polypeptides, including immunogenic fragments, are also considered within the scope of the invention. The biological activity of any given fragment of MCP-4 or MCP-5 may be readily determined by conducting an assay of, e.g., monocyte chemotaxis, as described herein. The preferred polypeptides of the invention are both substantially homologous to MCP-4 or MCP-5 and retain the biological activity of the relevant polypeptide, as described herein.

20 The nucleic acid molecules can encode a mammalian MCP-4 or MCP-5 polypeptide, such as those from a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat. Preferably, the nucleic acid molecule encoding MCP-4 encodes human MCP-4 and the nucleic acid molecule encoding MCP-5 encodes murine MCP-5 or, more preferably, human MCP-5.

25 The nucleic acid molecules can be placed under the control of a promoter, which may be constitutively active or induced by one or more external agents. The promoter can provide the means to achieve tissue-specific or cell type-specific expression of the nucleic acid molecules of the invention. Alternatively, or in

addition, the nucleic acid molecules can be operably linked to a DNA regulatory sequence. Skilled artisans will recognize that the nucleic acid molecules can be placed into a vector construct, such as a plasmid or viral vector, which may in turn be used to transduce living cells with the nucleic acid molecules of the invention.

5 Cells can be transfected with plasmid vectors by standard methods including, but not limited to, liposome-, polybrene-, or DEAE dextran-mediated transfection (see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neurosci. Lett. 117:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278, 1989), electroporation (Neumann et al., EMBO J. 7:841, 1980), calcium phosphate
10 precipitation (Graham et al., Virology 52:456, 1973; Wigler et al., Cell 14:725, 1978; Felgner et al., supra) microinjection (Wolff et al., Science 247:1465, 1990), or velocity driven microprojectiles ("biolistics"). Viruses known to be useful for gene transfer include adenoviruses, adeno associated virus, herpes virus, mumps virus, poliovirus, retroviruses, Sindbis virus, and vaccinia virus such as canary pox
15 virus.

The nucleic acid constructs described above are useful in a variety of ways. For example, the constructs may be used as a source of recombinantly produced MCP-4 or MCP-5 polypeptides. Alternatively, the constructs may be administered themselves in a therapeutic approach, as described below. In addition, the
20 constructs may be used to generate transgenic animals that overexpress, or fail to express, MCP-4 or MCP-5. The animal can be a mouse, a worm, or any other animal considered useful for research or drug development. Transgenesis has become routine in the art of molecular biology.

MCP-4 or MCP-5 polypeptides expressed by transfected cells can be
25 purified and injected into an animal, such as a rabbit, in order to generate polyclonal antibodies that specifically bind MCP-4 or MCP-5. Monoclonal antibodies may also be prepared using standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495, 1975; Kohler et al., Eur. J. Immunol. 6:292 and

-5-

6:511, 1976; Hammerling et al., *In Monoclonal Antibodies and T Cell Hybridomas*, Elsevier, NY, 1981). Alternatively, in various embodiments, an immunologically-active antibody fragment, such as an Fab', (Fab')₂, or genetically engineered Fv fragment (see U.S.S.N. 4,946,778, hereby incorporated by reference) may also be useful. Once generated, the antibodies may be purified according to standard methods and injected into a mammal, such as a human, in order to inhibit the inflammatory response caused by chemotaxis of various leukocytes, particularly monocytes.

Preferably, the nucleic acid molecules of the invention, cells that express these molecules, or a therapeutic composition containing the encoded polypeptides, are administered to a mammal in order to stimulate a local immune response. This approach would be particularly beneficial to mammals that are suffering from cancer. The cancer may be evident as, for example, a lymphoma (such as Hodgkin's lymphoma), a plasmacytoma, a melanoma, a sarcoma, or a tumor within the lung or gastrointestinal tract.

In the event that the desired result is inhibition (rather than stimulation) of a local immune response, a mutant MCP-4 or MCP-5 polypeptide, antibodies or fragments thereof that specifically bind MCP-4 or MCP-5, or antisense MCP-4 or MCP-5 oligonucleotides may be administered. The mutant MCP-4 or MCP-5 polypeptides may lack, for example, between one and ten of the amino acid residues present at the amino terminus of the mature polypeptides. Alternatively, the mutant polypeptides may contain additional amino acid residues, for example between 3 and 10 amino acid residues, at the amino-terminus of the mature polypeptides. Where amino acid residues are added, they may be random or they may be selected to have particular biological properties such as stability or hydrophilicity. Antisense MCP-4 or MCP-5 oligonucleotides preferably consist of at least eight nucleotides, and have a sequence that is the reverse and complement of that found within the genes encoding these polypeptides.

Suppression or inhibition of the local immune response would be beneficial when, for example, the mammal has been diagnosed as having asthma, chronic obstructive pulmonary disease, cystic fibrosis, sinusitis, rhinitis, atherosclerosis, glomerulonephritis, multiple sclerosis, or an inflammatory bowel disease.

5 The nucleic acid molecules of the invention are also useful in treating a mammal that is suffering from an infectious disease, such as acquired immune deficiency syndrome (AIDS) or malaria. Preferably, the method of treatment consists of administering to the infected mammal an MCP-4 or MCP-5 polypeptide, or a fragment thereof that is sufficient to bind the chemokine
10 receptors by which these infectious agents gain entry to the cell.

 The local immune response may also be modulated by administering a compound that modulates the chemotactic activity of MCP-4 or MCP-5. Examples of such modulators include interferon-gamma, tumor necrosis factor- α , interleukin-1, and interleukin-4. Additional modulatory compounds may be
15 discovered by, for example, the method described herein, whereby a population of cells that express MCP-4 or MCP-5 is obtained, a subset of these cells is contacted with a candidate modulatory compound and the level of MCP-4 or MCP-5 expression in the subset of cells is compared with the level of expression in an equivalent number of cells in the initial population that were not contacted with the
20 potential modulator. A difference in the level of MCP-4 or MCP-5 expression would indicate the presence of a compound that modulates MCP-4 or MCP-5 expression. Either gene expression or protein expression may be readily assessed by methods well known to skilled artisans. For example, mRNA expression could be assessed by Northern blot or RNase protection analyses and protein expression
25 could be assessed by Western blot analysis.

 By "polypeptide" is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation.

-7-

By "substantially pure" is meant that the substance in question, be it a nucleic acid molecule, a polypeptide, or an antibody, has been separated from the components that naturally accompany it. Typically, a polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-
5 occurring organic molecules with which it is naturally associated. Preferably, a preparation of MCP-4 or MCP-5 is at least 75%, more preferably at least 90%, and most preferably at least 99% pure, by weight. A substantially pure polypeptide may be obtained, for example, by extraction from a natural source (e.g., a mammalian cell), by expression of a recombinant nucleic acid encoding the
10 polypeptide, or by chemically synthesizing the polypeptide. Purity can be measured by any appropriate method, such as column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis. In reference to a DNA molecule, "substantially pure" means that the molecule is free of the genes that flank it in the naturally-occurring genome of the organism from which it is
15 obtained. The term therefore includes, for example, a recombinant DNA molecule which is incorporated into a vector; into an autonomously replicating plasmid or virus; into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by the polymerase chain reaction (PCR) or by restriction endonuclease digestion). It also
20 includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

By "substantially identical" to MCP-4 and MCP-5 is meant a sequence having at least 80% identity to the MCP-4 and MCP-5 sequences shown in Figs. 1A and 1B. Preferably, the identity is 90% and most preferably the identity is
25 95%.

By "operably linked" is meant that a gene or portion of a gene is connected to one or more regulatory elements, which are also a particular DNA sequences, in

-8-

such a way as to permit expression of the gene when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory element(s).

The term "transgenic" as used in reference to an animal or a cell, means an animal or cell into which a DNA sequence has been inserted by artifice and which becomes a part of the genome of the animal or cell.

By "biological activity" of MCP-4 or MCP-5 is meant the biological activity (preferably monocyte chemoattractant activity) which is at least 50% of that observed using MCP-4 or MCP-5, having the sequence shown in Figs. 1A and 1B respectively, in any of the assays describes herein. Preferably the activity is 80% of the activity observed with the MCP-4 and MCP-5 polypeptides of Figs. 1A and 1B, and most preferably, the activity is 95% of that observed with the MCP-4 and MCP-5 polypeptides of Figures 1A and 1B.

By "modulatory compound" or "modulator" is meant any compound that is capable of increasing or decreasing the expression or activity of MCP-4 or MCP-5. Expression may be modified at the level of transcription, translation, or post-translation. Activity may be modified at the level of receptor binding or within the cytoplasm of a cell. Activity may be assessed as, for example, monocyte chemotaxis per unit of MCP-4 or MCP-5 protein. Activity would be considered stimulated if, for example, the number of monocytes in a target tissue is at least 20% greater than the number of monocytes in a control, untreated tissue that is in all other substantive ways identical to the treated tissue. Conversely, activity would be considered inhibited if, for example, the number of monocytes in a target tissue is at least 20% less than the number of monocytes in a control, untreated tissue that is in all other substantive ways identical to the treated tissue.

Other features and advantages of the invention will be apparent from the following description and from the claims.

Brief Description of the Drawings

Fig. 1A is a schematic representation of the nucleotide sequence (bottom line; SEQ ID NO:1) and predicted amino acid sequence (top line; SEQ ID NO:2) of human MCP-4. The stop codon is indicated by asterisks; the predicted site for signal peptidase cleavage is indicated by an arrow; and a putative mRNA destabilizing sequence is underlined. The putative mature protein is numbered from +1 to +75.

Fig. 1B is a schematic representation of the nucleotide sequence (bottom line; SEQ ID NO:3) and predicted amino acid sequence (top line; SEQ ID NO:4) of murine MCP-5. The intron/exon borders are indicated by triangles; the ATTTA sequence (which may decrease mRNA stability) is singly underlined; the predicted polyadenylation signal is doubly underlined; and the predicted site for a signal peptidase cleavage is marked with an arrow (just 5' to the +1 site).

Fig. 2A is a schematic representation of the human MCP-4 amino acid sequence (SEQ ID NO:2), aligned with other chemokines having the CC motif (indicated by bold face type; SEQ ID NOs:5-14). The +1 predicts the mature N-terminus after signal peptidase cleavage (arrow), and gaps to maximize alignment are indicated by (-). The last 48 amino acids of murine MCP-1 have been omitted.

Fig. 2B is a schematic representation of the amino acid sequence of human MCP-4 (SEQ ID NO:2) murine MCP-5 (SEQ ID NO:4), and other mouse and human CC chemokines (SEQ ID NOs:5-8 and 14-16). Conserved amino acids are boxed, and the position of leader sequence cleavage is indicated by an arrow.

Figs. 3A and 3B are photographs of a Southern blot probed at high stringency (Fig. 3A) or low stringency (Fig. 3B) with a ³²P-labeled human MCP-4 cDNA probe. Human genomic DNA was digested with PstI (lane 1), BglII (lane 2), HindIII (lane 3), or EcoRI (lane 4).

-10-

Fig. 3C is a photograph of a Southern blot probed with a full-length MCP-5 cDNA probe. Mouse genomic DNA was digested with BamHI (lane 1), EcoRI (lane 2), XbaI (lane 3), or HindIII (lane 4).

In each of Figs. 3A - 3C, the position of molecular weight markers are indicated (in kb) on the left.

Fig. 3D is a representation of the genomic organization of the mouse MCP-5 gene, including selected restriction sites (top). The mature mRNA is also shown schematically (bottom), with the locations of the start (ATG) and stop codons (TGA) indicated.

Fig. 3E is a photograph of PCR products obtained by amplifying genomic DNA from C57BL/6J, *Mus spretus*, and heterozygous mice with primers in intron 2 of MCP-5.

Fig. 3F is a map depicting the location of the MCP-5 gene on mouse chromosome 11.

Fig. 4A is a photograph of a Northern blot that was probed with a ³²P-labeled human MCP-4 cDNA probe (upper blots) and a human β-actin cDNA probe (lower blots). Poly-A⁺ mRNA was isolated from the human tissues indicated. The position of molecular weight markers is shown (in kb) on the left.

Fig. 4B is a photograph of a Northern blot depicting MCP-5 expression in normal mouse tissues. The blot was probed sequentially with cDNA probes for MCP-5 and, as a control for RNA loading, rpl32 ribosomal protein. The positions of 18s and 28s RNA are indicated on the left.

Fig. 4C is a photograph of a Northern blot depicting MCP-5 expression in murine leukocytes and in tissues of mice that serve as models of pulmonary inflammation. Each lane represents an individual mouse from a representative experiment (n=3).

Fig. 4D is a photograph of a Northern blot depicting MCP-5 expression in activated macrophages (from the RAW 264.7 macrophage cell line) and

-11-

endothelial cells (SVEC cells). The cells were untreated (Ctl) or treated with IL-4, IFN γ , IL-1 β , or LPS as indicated.

Fig. 5A is a series of photographs of a Northern blot that was probed sequentially with MCP-4, MCP-1, VCAM-1 and β -Actin cDNA probes. Total RNA isolated from human umbilical vein endothelial cells was treated for the time shown with IFN γ , TNF α , IL-4, or IL-1 α , or a combination of IFN γ /TNF α , IFN γ /IL-4, or TNF α /IL-4.

Fig. 5B is a pair of photographs of a Northern blot hybridized sequentially with MCP-4 and GADPH cDNA probes. The samples consisted of total RNA, which was isolated from cells of the human respiratory epithelial cell line A549. The cells were either untreated (control) or treated with the cytokines listed above the corresponding lane of the blot (PMA, TNF α , IL-1 β , IFN γ , TGF α , and TGF β).

Fig. 5C is a pair of photographs of a Northern blot that was hybridized sequentially with MCP-4 and GADPH cDNA probes. The samples consisted of total RNA, which was isolated from cells of the human respiratory epithelial cell line A549 at various times after treatment with 0.1 ng/ml IL-1 β .

Fig. 5D is a pair of photographs of a Northern blot that was hybridized sequentially with MCP-4 and β -actin cDNA probes. Total RNA was isolated from the human respiratory epithelial cell line BEAS-2B either before (control), 6 hours, or 18 hours after stimulation with the cytokines listed above the corresponding lanes.

Fig. 6A is a pair of photographs of a Northern blot that was hybridized sequentially with MCP-4 and β -actin cDNA probes. Total RNA was isolated from untreated U937 cells (control; lane 1), U937 cells stimulated for 18 hours with IFN γ (lane 2), untreated HL60 cells (lane 3), an eosinophilic subline of HL60 cells that were cultured with butyric acid (HL60-Eosinophilic; lane 4), human peripheral blood mononuclear cells (lane 5), and neutrophils (lane 6).

Fig. 6B is a series of photographs of Northern blots that were hybridized with either MCP-4, RANTES, or β -actin probes. Total RNA was isolated from H9 T cells (lane 1), CD8⁺ HIV-specific cytolytic T cell clones that were unstimulated (lane 2) or stimulated with anti-CD3 (lane 3), and peripheral blood mononuclear cells cultured in the presence of PHA and IL-2 (lane 4).

Fig. 6C is a pair of photographs of a Northern blot that was hybridized sequentially with MCP-4 and β -actin cDNA probes. Total RNA was isolated from Jurkat Cells (lane 1), the RM3 subline of Raji cells (lane 2), freshly isolated purified peripheral blood eosinophils, either before (lane 3) or after (lane 4) culture with IL-3.

Fig. 7 is a photograph of an SDS-polyacrylamide gel (12.5%; Tris/Tricine) on which was electrophoresed recombinant MCP-4 His tagged protein (produced by *E. coli*) before factor Xa cleavage (lane 1; Coomassie stained), recombinant MCP-4 with the mature N-terminal Gln (PeproTech; lane 2; Coomassie stained), molecular weight standards (lane 3; values in kDa are indicated on the far left), and affinity purified MCP-4-FLAG protein (lane 4; Western blot).

Fig. 8 is a line graph depicting chemotaxis of human elutriated monocytes to recombinant MCP-4 (produced by *E. coli*) before (uncleaved; closed triangles) and after factor Xa cleavage (cleaved; open diamonds). The chemotactic response to MCP-1 is also shown (open circles). The results are expressed as the mean \pm SEM for replicate samples.

Fig. 9A is a panel of line graphs depicting chemotaxis of monocytes to MCP-4. Monocytes were subjected to chemotaxis in a modified Boyden chamber, and the number of cells that migrated through the membrane were counted (Y axis). Control chemotactic stimuli are indicated.

Fig. 9B is a panel of line graphs depicting chemotaxis of eosinophils to MCP-4. Monocytes were subjected to chemotaxis in a modified Boyden chamber,

-13-

and the number of cells that migrated through the membrane were counted.
Control chemotactic stimuli are indicated.

Fig. 9C is a panel of line graphs depicting chemotaxis of eosinophils.
Neutrophils were subjected to chemotaxis in the presence of MCP-4 in a modified
5 Boyden chamber, and the number of cells that migrated through the membrane
were counted (shown on left-hand graph). A control chemotactic stimulus, IL-8, is
also shown (right-hand graph).

In each of Figs. 9A, 9B, and 9C, the chemotaxis results are expressed as the
mean \pm SEM for replicate samples from one of five donors tested.

10 Figs. 9D - 9G are line graphs depicting chemotaxis of human peripheral
blood mononuclear cells (9D; n=4), mouse thioglycolate elicited peritoneal
macrophages (9E; n=1), mouse eosinophils (9F; n=5), and mouse neutrophils (9G;
n=3) following exposure to increasing concentrations of the indicated chemokines
in a modified Boyden chamber.

15 In each of Figs. 9D - 9G, the results are expressed as the mean \pm SEM for 8
hpf (high powered fields) counted in replicate wells.

Fig. 10A is a dark field photomicrograph of a section of tissue, obtained
from a human patient with hypertrophic sinusitis, that was hybridized with a
radiolabelled MCP-4 cRNA probe. "E" labels the epithelium.

20 Fig. 10B is a bright field photomicrograph of a section of tissue, obtained
from a human patient with hypertrophic sinusitis, that was hybridized with a
digoxigenin-labeled MCP-4 cRNA probe. The arrows point to mononuclear cells.

Fig. 11A is a series of tracings representing calcium flux stimulated by
MCP-4 in mononuclear cells. Fura-2-loaded cells were exposed sequentially to the
25 indicated chemokines with the concentration of each stimulus indicated in
parenthesis below the name of the chemokine. Calcium flux is reported as ratio
fluorescence of fura-2.

Fig. 11B is a series of tracings representing calcium flux stimulated by MCP-4 in neutrophils. Fura-2-loaded cells were exposed to chemokines, as described for Fig. 11A above, and changes in intracellular fluorescence were monitored.

5 Figs. 11C - 11E are a series of tracings representing calcium flux in human peripheral blood mononuclear cells (11C), eosinophils (11D), and neutrophils (11E) following sequential application of 100 nM of mMCP-5, mJE, hMCP-1, mMIP-1 β , mMIP-1 α , eotaxin, and mKC, as indicated.

10 Fig. 11F is a line graph depicting the concentration dependence of MCP-4 induced calcium flux in human mononuclear cells. The magnitude of the calcium transient peak induced by MCP-4 is plotted as a percentage of the maximal response observed for MCP-5.

15 Fig. 12A is a series of tracings representing the selectivity of various chemokine receptors to MCP-4. Calcium flux was monitored by the relative fluorescence of fura-2-loaded HEK 293 cells stably expressing cloned CC chemokine receptors. Each row of tracings corresponds to the receptor indicated on the left. Arrows indicate the time of addition of the indicated chemokine at 50 nM (a = MCP-4, b = MIP-1 α , c = MCP-1, and d = eotaxin).

20 Fig. 12B is a series of line graphs that identify CCR2 as a functional MCP-5 receptor. HEK-293 cells stably expressing human CCR2b (i, ii, and iii) or murine CCR2 (iv, v) were loaded with indo-1 AM, and intracellular calcium concentrations were monitored by ratio fluorescence in response to the indicated concentrations of MCP-5 (i, iv), JE (ii, v), and MCP-1 (iii).

25 Fig. 12C is a series of line graphs that illustrate desensitization of CCR2b by MCP-5. HEK-293 cells stably expressing human CCR2b were exposed to MCP-5 (i), MCP-1 (ii), or JE (iii) and subsequently challenged with 100 nM MCP-5, 100 nM MCP-1, or 100 nM JE.

Fig. 13 is a line graph in which the magnitude of the calcium transient peak induced by MCP-4 is plotted as a percentage of the maximal response observed for MCP-1 in the case of CKR2b (circles) and eotaxin in the case of CC CKR3 (squares).

5 Fig. 14A is a series of tracings depicting desensitization of calcium transients in HEK 293 cells stably transfected with CKR2b. Relative fluorescence was monitored before and during sequential addition of chemokines at the times indicated by the arrows. The first stimulus added (S1) for each tracing is indicated at the left of the row in which it is found. The second stimulus added (S2) is
10 indicated at the top of the column in which the tracing is found.

Fig. 14B is a series of tracings depicting desensitization of calcium transients in HEK 293 cells stably transfected with CKR3B. Fluorescence was monitored as described in the legend of Fig. 14A.

15 Detailed Description

Two new members of the β -chemokine family, MCP-4 and MCP-5, have been isolated and characterized. The expression pattern of the genes encoding these chemokines was examined in normal tissue and in a variety of clinically relevant circumstances, such as in cytokine stimulated endothelial, epithelial, and
20 hematopoietic cells, in hypertrophic sinus tissue, and in two *in vivo* models of pulmonary inflammation. In addition, the chemotactic activity of MCP-4 and MCP-5 proteins on various leukocytes, and the receptors through which this activity is exerted, are described.

The following examples are meant to illustrate, not limit, the invention.

25 Example 1: Cloning of Human MCP-4 and MCP-5 cDNA

A. Isolation of the human MCP-4 gene

A human MCP-4 cDNA was isolated from a heart cDNA library using a human eotaxin genomic probe, as follows. A 1.1 kb genomic fragment of the

-16-

human eotaxin gene containing exon 2 and the coding portion of exon 3 was ³²P-labeled with the Klenow fragment of DNA polymerase and used to probe a λ gt10 human heart cDNA library (Clontech, Palo Alto, CA). Approximately 10⁶ phage were plated, transferred to GeneScreen Plus (DuPont, Wilmington, DE), and hybridized for 18 hours at 42°C in a buffer containing 20 mM Tris (pH 7.5), 50% formamide, 10% dextran sulfate, 5X SSC, 1X Denhardt's solution (0.0002% (w/v) polyvinylpyrrolidone, 0.0002% (w/v) BSA, 0.0002% (w/v) Ficoll 400), and 100 mg/ml of heat-denatured herring sperm DNA solution. The filters were washed for 30 minutes at room temperature with 2X SSC and 0.1% SDS followed by a 30 minute wash at 60°C with 0.2X SSC and 0.1% SDS. Eight hybridizing plaques were identified and purified. The inserts were amplified by the polymerase chain reaction (PCR) using a pair of λ gt10 flanking primers. The PCR consisted of 30 thermocycles of 95°C for 60 seconds (during which the DNA was denatured), 55°C for 60 seconds (during which the primers annealed to the template), and 72°C for 60 seconds (during which a complementary sequence was polymerized). The amplified PCR products were subcloned into a pCRII vector (Invitrogen, San Diego, CA), and the sequence of both strands was obtained using SEQUENASE™ (USB-Amersham, Arlington Heights, IL). Alignment of the DNA sequences and homology analysis was performed by using the CLUSTAL analytical program and the GAP program (Genetics Computer Group at the University of Wisconsin, Madison, WI).

The MCP-4 cDNA was 823 bp long, consisting of a 34 bp 5' untranslated region, a 297 bp coding region, and a 492 bp 3' untranslated region (Fig. 1A). A single AUUUA sequence was identified in the 3' untranslated region (Fig 1A). This sequence motif has been shown to decrease the stability of cytokine mRNA (Shaw et al., Cell 46:659-667, 1986). The entire cDNA sequence of human MCP-4 was compared with the nucleotide sequence of the known human chemokines. MCP-4 was found to be 62%, 58%, and 57% identical to MCP-1,

-17-

MCP-3, and eotaxin, respectively (Table 1). The nucleotide sequence of human MCP-4 was also compared to known mouse chemokines and found to be most homologous to eotaxin (57% identical), and 54% and 51% identical to MCP-3 and MCP-1, respectively.

Table 1 Homology of Human MCP4 with other Chemokines

Chemokine	Amino Acid		Nucleic Acid Identity (%)
	Identity (%)	Similarity (%)	
Hu MCP1	65	79	62
Hu MCP2	57	70	ND
Hu MCP3	65	77	58
HU EOT	66	76	57
Hu RANTES	32	57	41
Hu MIP-1 α	39	54	45
Hu MIP-1 β	39	61	41
Hu-IL-8	28	53	27
Mu MCP1	54	69	51
Mu MCP3	53	70	54
Mu EOT	54	66	57
Mu RANTES	35	59	42

The human MCP-4 cDNA encodes a 99 amino acid protein containing a highly conserved 23 amino acid signal peptide (Fig 1A). Signal peptidase cleavage is predicted to occur after the sequence, Pro-Gln-Gly-Leu-Ala, which is invariant in human MCP-1, -2, -3, and eotaxin (Fig. 2A). The resulting 76 amino acid sequence is predicted to have an N-terminal Gln, which is characteristic of the MCP family. The putative mature protein is predicted to have a molecular weight of 8,599 Da, a pI of 10, and appears to lack N-linked glycosylation sites. At the amino acid level, human MCP-4 exhibits 66%, 65%, 57%, and 65% identity with

-18-

human eotaxin, MCP-1, MCP-2, and MCP-3, respectively, and has 54%, 54%, and 53% identity with mouse eotaxin, MCP-1 and MCP-3, respectively. Thus, human MCP-4 is as closely related to eotaxin as it is to proteins in the MCP family. However, in contrast to eotaxin, MCP-4 has an N-terminal Gln residue and it lacks the two amino acid N-terminal gap that is characteristic of the eotaxin proteins.

B. Isolation of the murine MCP-5 gene

Human MCP-4 cDNA was radiolabelled and used as a probe to screen a 129SV mouse genomic library (Stratagene, La Jolla, CA). Approximately 10^6 phage were plated, transferred to GeneScreen Plus (DuPont, Wilmington, DE), hybridized for 18 hours at 50°C in a low stringency hybridization buffer (0.6M NaCl, 80 mM Tris-HCl, 4 mM EDTA, 0.1% (w/v) sodium pyrophosphate, 0.1% (w/v) SDS, 10X Denhardt's solution, 100 µg/ml denatured herring sperm DNA) at 50°C and washed at 60°C in 1X SSC/0.1% SDS. In order to exclude JE, the putative murine orthologue of human MCP-1, the filters were rehybridized as described with a full-length JE cDNA fragment and washed at 65°C in 0.1X SSC/0.1% SDS. Fifteen plaques, which hybridized more strongly with the human MCP-4 probe than with the murine JE probe, were analyzed by PCR using two sets of degenerate oligonucleotides corresponding to highly conserved regions of murine and human CC chemokines and the MCP-eotaxin subfamily. The first set was designed to amplify Exon 1-2 and consisted of a 5' oligomer (5'-CTTCTGKGYCTGCTGYTCA-3'; SEQ ID NO:17) and a 3' oligomer (5'-ACAGCYTYYYDGGGACA-3'; SEQ ID NO:18). The second set was designed to amplify Exon 2-3 and consisted of a 5' oligomer (5'-TGTCCCHRRRARGCTGT-3'; SEQ ID NO:19) and a 3' oligomer (5'-GSKTCAGCRCAGAYYTC-3'; SEQ ID NO:20). The reactions were heated to 95°C for 5 minutes and then subjected to 30 rounds of the following thermocycle: 94°C for 1 minute, 45°C for 1 minute and 72°C for 1.5 minutes. The final round of extension at 72°C was prolonged to 8 minutes.

-19-

When the first set of primers was employed, five of the fifteen plaques were shown to contain DNA that was amplified as an 800 bp PCR product. These products were subcloned into the pCRII vector (Invitrogen, San Diego, CA) and sequenced (Sequenase Kit, United States Biochemical, Cleveland, OH). All five subclones contained novel, overlapping sequence that appeared to be homologous to members of the MCP subfamily.

In order to determine the complete structure of the MCP-5 cDNA, 5' and 3' RACE PCR was performed using RNA isolated from IFN γ -treated RAW 264.7 cells. The 5' and 3' ends of the cDNA for murine MCP-5 were isolated using a 3' oligonucleotide in exon 2 (5'-CTGGCTGCTTGATTCTCCTGT-3'; SEQ ID NO:21), a 5' oligonucleotide at the end of exon 1 (5'-CAGTCCTCAGGTATTGGCTGG-3; SEQ ID NO:22), and the MarathonTM cDNA Amplification Kit (Clontech, Palo Alto, CA). The amplified products were cloned into the pCR2.1 vector (Invitrogen, San Diego, CA) and sequenced. Based on the sequence obtained, oligonucleotides capable of amplifying full-length cDNA from IFN γ -treated RAW cell poly A⁺ RNA were synthesized using the 5' oligomer 5'-AGCTTTCATTTCTGAAGTCTTTG-3'(SEQ ID NO:23) and the 3' oligomer 5'-TAGATTCGGTTTAATTGGCCC-3'(SEQ ID NO:24). The products produced by PCR with these oligonucleotides were cloned into pCR2.1 and sequenced.

The cDNA was 514 bp long with an open reading from that encoded 104 amino acids. The 5' region of the cDNA encoded a 22 amino acid hydrophobic leader sequence whose cleavage site was predicted to occur at a position similar to the other MCPs and eotaxin (Figs. 1B and 2B) resulting in a mature protein of 9.3 kDa with a pI of 9.4. The 3' untranslated region contained a single polyadenylation signal of a rare type also found in human eotaxin (ATTAAA) and four mRNA destabilization signals (ATTTA; Fig. 2B) that have been reported to decrease the mRNA stability of other cytokine mRNAs (Shaw et al., Cell 46:659-667, 1986).

-20-

The sequence of murine MCP-5 has been deposited with GenBank and assigned the accession number U66670. The sequence comparison shown in Fig. 2B was generated using the program SeqVu (from The Garvin Institute of Medical Research, Sydney, Australia). Sequences were aligned for maximal homology, using the positions of the four conserved cysteine residues as fixed points.

The sequence of murine MCP-5 is most homologous to human MCP-1. The percent amino acid/nucleic acid identity is shown in Table 2. These figures depict comparison of the open reading frames and the full length cDNAs using the GAP program (supplied by the Genetics Computer Group at the University of Wisconsin Madison, WI), which uses the algorithm of Needleman and Wunsch to maximize the number of matches and minimize the number of gaps in two complete sequences. ND indicates that the percent identity was not determined. Like human MCP-1, murine MCP-5 does not contain the additional serine/threonine rich glycosylated 49 amino acid C-terminal extension that JE uniquely possesses (Fig. 2B). MCP-5 is unique among the MCP proteins in that its N-terminal amino acid is predicted to be glycine, a feature that it shares with human eotaxin (Figs. 1B and 2B).

-21-

TABLE 2

	mMCP5	mJE	mMCP3	mBot	hMCP1	hMCP2	hMCP3	hMCP4	hBot
mMCP5		47/50	58/57	49/53	66/64	56/ND	60/62	56/58	58/59
mJE	47/50		49/54	49/51	52/63	53/ND	52/52	54/51	49/50
mMCP3	58/57	49/54		46/48	59/60	51/ND	61/67	53/67	54/54
mBot	49/53	49/51	46/48		53/54	52/ND	57/53	54/50	59/55
hMCP1	66/64	52/63	59/60	53/54		62/ND	74/66	65/61	71/63
hMCP2	56/ND	53/ND	51/ND	52/ND	62/ND		58/ND	57/ND	61/ND
hMCP3	60/62	52/52	61/67	57/53	74/66	58/ND		64/58	70/63
hMCP4	56/58	54/51	53/67	54/50	65/61	57/ND	64/58		66/58
hBot	58/59	49/50	54/54	59/55	71/63	61/ND	70/63	66/58	

Example 2: Gene Analysis and Chromosomal Location

A. Southern blot analysis of MCP-4

High molecular weight genomic DNA was isolated from human peripheral blood leukocytes (PBMCs), and separate samples were digested with one of four restriction endonucleases: PstI, HindIII, BglII, or EcoRI. Approximately 20 mg of digested DNA were electrophoresed on a 0.8% agarose gel, transferred to GeneScreen Plus, and hybridized for 18 hours at 42°C with the MCP-4 cDNA probe described in Example 1. The blots were first washed at low stringency (2X SSC, 0.1% SDS, 50°C) and then at high stringency (0.1X SSC, 0.1% SDS, 65°C) for 30 minutes each. This analysis revealed that human MCP-4 is a single copy gene (Fig. 3A). Furthermore, under highly stringent hybridization and washing conditions, the MCP-4 cDNA can be used as a probe to uniquely detect MCP-4. Low stringency Southern blot analysis (Fig. 3B) revealed multiple bands, which represent closely related β -chemokine genes.

In order to determine the chromosomal location of the MCP-4 gene, PCR-based screening of the National Institute of General Medical Sciences (NIGMS) somatic cell hybrid panel #2 (available from the A.T.C.C., Rockville, MD) was performed using MCP-4 specific oligonucleotide primers (5'-TCAGCCAGATGCACTCAACG-3' (SEQ ID NO.:25) and 5'-TGGAAAAGTCATTTCACGTA-3' (SEQ ID NO.:26)) from exons 2 and 3, respectively. The reaction was performed using 100 ng of template DNA, which was denatured initially at 94°C for 2 minutes and then subjected to 30 repetitions of the

-22-

following thermocycle: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60 seconds. The reaction products were separated by electrophoresis on a 1% agarose gel, and visualized by staining with ethidium bromide.

Oligonucleotide primers specific for human MCP-4 genomic sequences were also used to amplify human, mouse, and hamster genomic DNA. No product was seen when rodent DNA was used. However, an ~850 bp product was observed in human genomic DNA and in a somatic cell hybrid line containing human chromosome 17 as its only human chromosome. The other rodent-human hybrid cell lines did not contain DNA that could be amplified with the designated primers. Thus, MCP-4 is located on human chromosome 17.

B. Southern blot analysis of MCP-5

Samples containing approximately 10 µg of mouse genomic DNA were digested separately with one of four restriction endonucleases: BamHI, EcoRI, XbaI, or HindIII. The digests were then electrophoresed through an agarose gel (0.8%), transferred to GeneScreen Plus™, hybridized under conditions of high stringency (50% formamide, 10% dextran sulfate, 5X SSC, 1X Denhardt's solution, 1% SDS, 100 µg/ml denatured herring sperm DNA, and 20 mM Tris at 42°C) with a radiolabeled MCP-5 probe, and washed for 40 minutes at 55°C in 0.2X SSC/0.1% SDS. The blot was then exposed to X-ray film. A photograph of the resulting autoradiogram is shown in Fig. 3C. A schematic representation of the genomic organization of the mouse MCP-5 gene, including the intron-exon structure, selected restriction sites, and the mature mRNA is shown in Fig. 3D.

C. The chromosomal location of MCP-5

The chromosomal location of MCP-5 was determined by single-stranded conformational polymorphism (SSCP) analysis using a pair of PCR primers in intron 2 that detected a polymorphism when using DNA from C57BL/6J and *Mus spretus* mice (Fig. 3E). The 5' "sense" oligonucleotide used was 5'-TTACAGGTCAGGTCCTTACT-3' (SEQ ID NO:27) and the 3' "anti-sense" oligonucleotide was 5'-CTCCTTATCCAGTATGGTCCTG-3' (SEQ ID NO:28).

A panel of genomic DNA from 94 interspecific backcross animals between (C57BL/6J X SPRET/Ei)F₁ X SPRET/Ei (Jackson BSS) was used to map the MCP-5

-23-

gene based on the SSCP polymorphism. The MCP-5 gene cosegregated with *Scya7* (Fic) and *Scya11* (eotaxin) in this cross, placing it between D11Mit markers 7 and 36 on Chromosome 11. A comparison with the consensus map from the Mouse Genome Database (Fig. 3F) revealed this to be the region of Chromosome 11 containing the CC chemokine gene cluster designated *Scya1-11*. The MCP-5 gene has been assigned the designation *Scya12* (Fig. 3F). In Fig. 3F, the right-hand panel shows a segment of the central part of the map of chromosome 11 from the Jackson BSS cross described, containing approximately 1500 loci. The data are: proximal-Nos2-1 recombinant/94 animals (1.1 +/- 0.1 cM)-*Scya12*-2 recombinants/94 animals (2.1 +/- 1.5 cM)-Mpmv4-distal. The left-hand panel of Fig. 3F shows the Mouse Genome Database consensus map, wherein the estimated relative positions of the loci are given at cM offset from the centromere. *D11Mit4* is offset at 37, *Scya11* is offset at 45.4, and *D11Bir12* is offset at 53. Other CC chemokines are shown and referred to as *Scy1-11*.

Example 3: MCP-4 and MCP-5 Gene Expression

A. MCP-4 mRNA Expression in Normal Human Tissue

In order to examine the expression of human MCP-4 in different tissues, Northern blot analysis was performed as follows. Northern blots of multiple human tissue samples were obtained from Clontech and hybridized in the buffer described in Example 1 at 42°C for 18 hours. The blots were then washed with 0.2X SSC and 0.1% SDS at 65°C for 60 minutes. In order to control for potential variations in the quantity of RNA loaded, the blots were stripped by washing with 0.1X SSC and 0.1% SDS at 90°C for 60 minutes and rehybridized with either a human β -Actin probe or a glyceraldehyde-3 phosphate dehydrogenase (GADPH) cDNA probe (Clontech).

This analysis revealed an ~850 bp transcript that probably corresponds to the mature human MCP-4 mRNA. The highest levels of constitutive MCP-4 expression were observed in normal human small intestine, colon, and lung with lower but clearly detectable expression in heart, placenta, and thymus. Lower levels of expression were also seen in muscle, kidney, pancreas, prostate, liver, testis and ovary. However, no expression was detected in brain, spleen or peripheral blood leukocytes (Fig. 4A).

B. Expression of MCP-4 in
Inflamed Human Nasal Tissue

To examine the possibility that MCP-4 plays a role in allergic inflammation, MCP-4 expression was analyzed by *in situ* hybridization of nasal tissue obtained from
5 nine patients with sinusitis and from six normal controls. All patients were adults between the ages of 19-45, who were selected because they suffered from chronic sinusitis for more than one year, (Hamid et al., Proc. Natl. Acad. Sci. USA 84:6760-6764, 1987). Patients were given an allergy skin test and, based on the result, placed in either an allergic or non-allergic subgroup. Biopsies of 2-3 mm were obtained from the maxillary
10 sinuses of patients with chronic sinusitis and nasal mucosal biopsy specimens were taken from the inferior and middle turbinates of the six control subjects. The tissue was fixed by immersion in 4% paraformaldehyde for 2 hours, washed, embedded, and cut into sections (each 8 μ m thick) before processing for *in situ* hybridization.

In situ hybridization was performed as previously described (Hamid et al., J. Clin. Invest. 87:1541-1546, 1991; Hamid et al., J. Clin. Invest. 94:870-876, 1994). Briefly,
15 ³⁵S-labelled RNA probes coding for MCP-4 mRNA were applied to permeabilized tissue sections, and the cRNA-mRNA hybrid was visualized using autoradiography. To characterize the MCP-4 mRNA-positive cells, particularly the inflammatory cells, digoxigenin-labeled probes were used. In a blind study, the MCP-4 mRNA signal was
20 assessed in at least two sections from each subject. The hybridization signal in the epithelium was presented as the percentage of positive epithelial cells within the total epithelium. The mRNA positive cells in the subepithelium were expressed as the mean number of positive cells/high power field (0.20 mm²). As a negative control, sections were hybridized with sense probes or pretreated with RNase prior to hybridization with
25 anti-sense probes.

The level of MCP-4 mRNA expression was significantly higher in the tissue obtained from patients with sinusitis (both in the epithelial and subepithelial tissue) than in the tissue obtained from unaffected individuals. A quantitative assessment of the MCP-4 mRNA-positive cells in these patients is shown in Table 3. There was not a
30 significant difference between the expression of MCP-4 in the tissue obtained from individuals in the allergic and non-allergic groups. Most of the mRNA expression was

-25-

localized to the epithelium, particularly the basal layer. Most of the positive cells among the inflammatory infiltrate were mononuclear cells with abundant cytoplasm, a feature that is consistent with macrophage morphology. There were other positive cells, however, including small mononuclear cells, which could be lymphocytes, and granulocytes, which could be either eosinophils or neutrophils.

TABLE 3

Tissue studied	No. of cases studied	Mean % epithelium +ve for MCP-4 mRNA	Mean no. of inflammatory cells/field +ve for MCP-4 mRNA in the subepithelium
Allergic sinusitis	4	71.8 ± 10.7	12 ± 1.5
Non-allergic sinusitis	5	77.5 ± 10.0	13.3 ± 1.3
Normal control	6	14.6 ± 3.8	3.4 ± 0.3

C. MCP-5 Expression in Normal Murine Tissue and Murine Cell Lines

RNA was isolated from the organs of BALB/c mice by lysing the tissue in guanidinium isothiocyanate and pelleting the RNA through a 5.7 M CsCl₂ cushion (Chirgwin et al., Biochem. 18:5294-5299, 1979). The polyA⁺ fraction was isolated from total RNA by oligo-dT cellulose chromatography (Pharmacia, Piscataway, NJ). RNA STAT-60 (Tel Test-B Inc., Friendswood, TX) was used to isolate RNA from mouse leukocytes and cell lines.

To generate a Northern blot, 10 µg of total RNA was fractionated on a 1.2% agarose gel containing 0.7% formaldehyde and transferred to a GeneScreen™ membrane. The membrane was then exposed to ³²P-dCTP-labeled MCP-5 or JE cDNA probes under hybridization conditions. A probe for the ribosomal protein rpL32 (Shen et al., Proc. Natl. Acad. Sci. USA 89:8240-8244, 1992) was used as a control for the quantity of RNA loaded. Hybridization was performed under conditions of high stringency, and the membrane was washed at 55°C in 0.2X SSC, 0.1% SDS for 40 minutes. SVEC cells, from an SV40 virus-immortalized murine endothelial cell line and RAW 264.7 cells (American Type Culture Collection, Rockville, MD) were cultured for 6 hours or 18 hours in DMEM supplemented with 10% iron fortified calf serum (without additions)

-26-

that contained either 200 U/ml recombinant murine IFN γ (Genentech Inc., San Francisco, CA), 5 ng/ml recombinant murine IL-1 β (Genzyme, Cambridge, MA), or 10 ng/ml recombinant murine IL-4 (Genzyme, Cambridge, MA). Mouse bone marrow-derived mast cells were obtained by culturing mouse bone marrow from FVB mice in the presence of 50% WEHI-3-conditioned medium for 4 weeks. Mast cells were sensitized with IgE anti-TNP at 50 μ g/ml and either stimulated with TNP-BSA at 100 μ g/ml for 4 hours at 37°C or treated with 2.5 mg/ml of concanavalin A (ConA) for 4 hours at 37°C.

The procedures described above revealed an approximately 550 bp transcript that corresponds to the mature mouse MCP-5 mRNA. The highest levels of constitutive MCP-5 expression were observed in normal lymph nodes. MCP-5 mRNA was also seen in heart, lung, breast, salivary glands, thymus, colon, kidney, small intestine, and brain (the salivary gland and breast tissue contained lymph nodes). In contrast, no expression was detected in spleen, skeletal muscle, bone marrow, liver, or peripheral blood leukocytes (Fig. 4B).

The expression of MCP-5 and JE were compared in the mouse tissues listed above because these proteins have similar biological profiles and bind the same receptor. The highest constitutive expression of JE was seen in the salivary gland with low levels detected in other organs, such as lymph nodes. The 550 and 800 bp JE transcripts correspond to known 3' splice variants (Kawahara et al., J. Biol. Chem. 264:679-682, 1989).

As shown in Fig. 4C, MCP-5, JE, and rpL32 expression was also examined in subsets of leukocytes. RNA was isolated from eosinophils purified from the spleens of CD5-IL5 transgenic mice (Eos), bone marrow-derived mast cells that were either untreated (Ctl) or stimulated with either IgE (anti-TNP and TNP-BSA (IgE)), or ConA (ConA). In addition, RNA was harvested from resident peritoneal macrophages (RM Φ), elicited peritoneal macrophages (EM Φ ; 76% MNC, 24% PMN), and elicited peritoneal neutrophils (EN Φ ; 95% PMN, 5% MNC). Blots were hybridized and washed sequentially under conditions of high stringency with MCP-5, JE and rpL32 cDNA probes and exposed for 14 days, 3 days, or 18 hours, respectively.

No expression was detected in eosinophils, bone marrow-derived mast cells, or resident peritoneal macrophages. Furthermore, stimulation of these mast cells with either

-27-

IgE or ConA did not induce MCP-5 expression. However, ConA induced the expression of JE (Fig. 4C) and both IgE and ConA treatment induced expression of murine CCR1 (Gao et al., Biochem. Biophys. Res. Comm. 223:679-684, 1996). Activated macrophages, which were elicited in the peritoneal cavity by treatment with thioglycolate, expressed significant levels of MCP-5 mRNA. Neutrophils, which were elicited in the peritoneal cavity by treatment with sodium casein, also appeared to express MCP-5 mRNA. MCP-5 mRNA was not detected in either an unstimulated or stimulated allogeneic cytolytic CD8⁺ T cell clone.

The ability of various stimuli to induce MCP-5 mRNA in the RAW264.7 macrophage cell line was evaluated because it appeared that activated macrophages were a primary source of MCP-5 mRNA. RNA was harvested from cells that were either untreated or treated for 18 hours with interferon- γ (IFN γ at 200 U/ml), or LPS (lipopolysaccharide) at 0.1, 1.0, 10, or 100 ng/ml. The RNA was then analyzed on Northern blots that were hybridized with MCP-4, JE, and rpL32 cDNA probes, washed sequentially under conditions of high stringency, and exposed for 7 days, 3 days, and 18 hrs, respectively.

The expression of MCP-5 was also examined in cytokine-stimulated murine endothelial cells (SVEC cells). MCP-5 was not induced in SVEC cells by IFN γ , IL-4 (10 ng/ml), or IL-1 β (5 ng/ml), while JE was induced by IFN γ and IL-4 (Fig. 4D) and eotaxin was induced by IFN γ (Rothenberg et al. Proc. Natl. Acad. Sci. USA 92:8960-8964, 1995). JE was similarly expressed in activated macrophages and induced in RAW cells by LPS and IFN γ (Fig. 4D).

D. MCP-5 mRNA Expression in Murine Models of Pulmonary Inflammation

In order to determine whether MCP-5 is associated with the immune response *in vivo*, MCP-5 expression was examined in the lungs of mice that had been infected with *Nippostrongylus brasiliensis* and in a murine model of OVA-induced pulmonary inflammation (Fig. 4C).

The *N. brasiliensis* model was generated as described by Coffman et al. (Science 245:308-310, 1989). Briefly, twelve week old female BALB/cJ mice were injected with 750 third stage *N. brasiliensis* larvae, their lungs were harvested 7, 10 or 14 days later,

-28-

and RNA was extracted from the tissue and analyzed by Northern blotting. The level of MCP-5 mRNA was markedly increased by day 7. The expression level peaked on day 10 and returned to control levels by day 14. MCP-5 mRNA accumulation preceded the peak recruitment of pulmonary macrophages, neutrophils, and eosinophils that characterize the granulomatous immune response to this pathogen (Coffman et al., *supra*).

The aerosolized OVA model is generated as follows (see also MacLean et al., J. Exp. Med., in press, 1996). BALB/cJ mice that were between 5 and 10 weeks old were immunized with 10 µg of OVA (Sigma Chemical Co., St. Louis, MO) and 1 mg of aluminum hydroxide (via an intraperitoneal injection) on days 0, 7, and 14. Control mice were "sham-immunized" by treatment with aluminum hydroxide only. An aerosol challenge with OVA (50 mg/ml in sterile sale) was administered 7-10 days after the final immunization. The mice were sacrificed 3, 6, 24, or 48 hours after the aerosol challenge, their lungs were harvested, and RNA was extracted from the tissue. At least 3 mice were present in each group and at each time point of harvest.

MCP-5 mRNA was detected in the OVA-immunized mice 3 hours after aerosol challenge (Fig. 4C; left-most lane labeled IC) and remained at an elevated level at the 48 hour time point (right-most lane labeled IC). In contrast, MCP-5 mRNA in challenged, sham-immunized mice (SC) remained at the same level as before the aerosol challenge. In this model, as following infection with *N. brasiliensis*, the accumulation of MCP-5 mRNA preceded the peak accumulation of pulmonary macrophages, lymphocytes and eosinophils that characterize the immune response.

Expression of JE was also elevated in both models of pulmonary inflammation. However, in the OVA model, levels of JE mRNA returned to baseline by 48 hours but MCP-5 levels remained elevated.

Example 4: Cytokine Regulation of MCP-4 in Endothelial and Epithelial Cells

RNA was isolated from cultured cells using RNA-STAT 60 (Tel Test-B Inc., Friendswood, TX), according to the manufacturer's recommendations. Total RNA (20 mg) was fractionated on a 1.2% agarose gel containing 0.2 M formaldehyde, transferred to GeneScreen™, and hybridized with ³²P-dCTP Klenow-labeled, random primed probes. A human MCP-1 probe was generated from a full length human MCP-1 cDNA isolated

from a human lung library (Clontech), and the template for a human vascular cell adhesion molecule-1 (VCAM-1) probe was as described in Cybulsky et al. (Am. J. Pathology, 138:815-820, 1991).

The capacity of human umbilical cord endothelial cells (HUVEC) to express MCP-4 mRNA was evaluated as follows. Human umbilical vein endothelial cells (HUVEC) were obtained at passage two from Clonetics (San Diego, CA) and treated at passage three with the following cytokines: IL-1 α (5 ng/ml), IL-4 (20 ng/ml), IFN γ (100 ng/ml), and TNF α (10 ng/ml; all cytokines were obtained from Genzyme, Cambridge, MA).

These cells had no detectable constitutive MCP-4 expression, but IL-1 α , TNF α and, to a lesser extent, IFN γ stimulated the accumulation of MCP-4 mRNA within six hours. These levels decreased within 18 hours of stimulation (Fig. 5A). In contrast to MCP-1 expression, the expression of human MCP-4 was not significantly increased in HUVECs by stimulation with IL-4 (Fig. 5A). TNF α and IFN γ acted synergistically, and IL-4 prolonged the TNF α -induced accumulation of eotaxin mRNA. Human MCP-1 and human vascular cell adhesion molecule (VCAM-1) were used as controls for HUVEC's responsiveness to the cytokines tested, and β -actin was used as a control for RNA loading (Fig. 5A).

The ability of two respiratory epithelial cell lines, BEAS-2B and A549, were also tested for their ability to express MCP-4 mRNA in response to cytokine stimulation. These cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)/F-12 (BEAS-2B) and F12K (A549) medium. Epithelial cells grown to confluence were stimulated with increasing doses of either IL-1 β , TNF α , or IFN γ , or with 10 nM phorbol 12-myristate 13-acetate (PMA), transforming growth factor- α (TGF α ; 10 ng/ml) or TGF β (10 ng/ml). Human cells U937 and HL60 were obtained from the American Type Culture Collection (A.T.C.C., Rockville, MD) and maintained in DMEM. MCP-4 mRNA expression was not detected by Northern analysis in A549 cells in the absence of cytokine stimulation. However, stimulation of the cells with 0.1 ng/ml of IL-1 β or 10 ng/ml of TNF α for 4 hours induced the accumulation of a distinct ~850 bp MCP-4 mRNA species (Fig. 5B). The addition of 10 nM PMA to the medium was associated with the presence of a faint but detectable MCP-4 mRNA signal. However, MCP-4

-30-

mRNA was not detected after 4 hours of stimulation with 10 ng/ml IFN γ , 10 ng/ml TGF α , or 5 ng/ml TGF β (Fig. 5B). Treatment of A549 cells with 10 ng/ml of TNF α induced maximal MCP-4 mRNA expression at four hours, which declined over the subsequent 48 hours (Fig. 5C). Identical results were obtained for IL-1 β -induced accumulation of MCP-4 in A549 cells. Likewise, the addition of TNF α similarly increased MCP-4 mRNA expression in BEAS-2B cells six hours after stimulation, with decreasing levels after 18 hours of stimulation (Fig. 5D). IFN γ acted synergistically with TNF α and IL-1 to induce MCP-4 mRNA accumulation in both BEAS-2B cells (Fig. 5D) and A549 cells. Furthermore, while IL-4 alone did not induce a detectable expression of MCP-4 in the BEAS-2B line, it clearly acted synergistically with TNF, IL-1 and IFN γ (Fig 5D).

Example 5:

Expression of MCP-4 in Leukocytes

The expression of eotaxin mRNA was examined in U937 cells, a monocytic tumor line, in HL60 cells, a myelocytic tumor line, and in peripheral blood leukocyte subtypes by the method described in Example 4. U937 cells constitutively expressed MCP-4 mRNA, which was unaffected by IFN γ treatment (Fig. 6A). MCP-4 mRNA was undetectable by Northern blot analysis of total RNA in untreated HL60 cells. However, there was a detectable MCP-4 signal in an eosinophilic subline of HL60 (available from the A.T.C.C., Rockville, MD). These cells were maintained in Iscove's Modification of DMEM supplemented with 0.5 mM butyric acid (Sigma Chemical Co., St Louis, MO) as described by Tomonaga et al., 1986). The medium was supplemented with 10% iron-fortified calf serum (MediaTech, Hendon, VA), 50 U/ml penicillin, 50 mg/ml streptomycin, and 2 mM L-glutamine. Peripheral blood mononuclear cells, peripheral blood neutrophils, untreated peripheral blood eosinophils, peripheral blood eosinophils cultured in the presence of IL-3 for 3 days, Jurkat and H9 T cells, and RM3 B cells did not express detectable MCP-4 mRNA (Fig. 6A, 6B, and 6C). However, MCP-4 mRNA was detected in peripheral mononuclear cells cultured in the presence of PHA and IL-2 for 3 days (Fig 6B). While three HIV-specific cytolytic CD8⁺ T cell clones induced the expression of RANTES upon activation with an anti-CD3 monoclonal antibody, MCP-4 mRNA was not detected (data for one of the three clones tested is shown in Fig 6B).

Example 6: Generation of Biologically
Active Recombinant Human MCP-4 Protein

To examine the biological properties of human MCP-4, the protein was expressed and purified from COS cells and *E. coli* cells.

5 A. Production of Recombinant MCP-4 in *E. coli*

DNA encoding recombinant human MCP-4, beginning with the putative mature amino-terminal glutamine at position 24 and ending with the carboxy terminal threonine at position 98, was amplified by PCR using the human MCP-4 cDNA as a template. The oligonucleotide primers used were designed to amplify a sequence that contained BamHI sites on both ends, and that would encode a protein with an amino-terminal factor Xa site (IEGR). Amplified cDNA was subsequently sub-cloned using a TA cloning kit (Invitrogen) and sequenced. The construct was liberated by BamHI digestion, cloned into the BamHI sites of vector PQE8 (Qiagen Inc, Chatsworth, CA), and then transformed into the *E. coli* strain M15. Expression of MCP-4 in pQE8 resulted in a fusion protein containing an amino-terminal Met-Arg-Gly-Ser-(His)₆ (SEQ ID NO.:29) tag, which was purified essentially as described (Rothenberg et al., Mol. Med. 2:334-348, 1996), with the following minor modifications. Recombinant M15 *E. coli* containing the PQE8 plasmid engineered to express human MCP-4 were induced with isopropyl β -D-thiogalactopyranoside (IPTG) for 2 hours. Following centrifugation, the bacterial pellet was resuspended in 50 mM Tris (pH 8.0), 0.2 M NaCl, 2 mM EDTA, 0.1 mM PMSF, 1 mM benzamidine, and 5 mM β -mercaptoethanol at 5 ml/gram of wet bacteria. Lysozyme was added to a final concentration of 0.2 mg/ml and the bacterial suspension was incubated on ice for 20 minutes. Triton-X-100 was then added to 1%, and the incubation was resumed for an additional 10 minutes. The suspension was sonicated on ice and centrifuged at 10,000 x g for 20 minutes at 4°C. The pellet was resuspended in 6 M guanidine HCl, 0.1 M sodium phosphate and 0.01 M Tris HCl (pH 8.0), and applied to a nickel-NTA chromatography column (ProBond™, Invitrogen) as described (Rothenberg et al., Mol. Med. 2:334-348, 1996). Recombinant MCP-4 was eluted from the column with 8 M urea buffer (described above) at pH 8.0 containing 0.25 M imidazole. The protein was further purified by high pressure liquid chromatography (HPLC) on a C4 reverse phase semi-preparative column (#214TP510, Vydac, Hesperia CA). Buffer A

-32-

consisted of Milli Q dH₂O/0.1% trifluoroacetic acid (TFA), and buffer B consisted of 95% acetonitrile/0.1% TFA. The sample was loaded in 10% buffer B and run on a linear gradient on a Waters HPLC system. The gradient went from 10% to 20% buffer B over 5 minutes, and from 20% to 90% buffer B over 27 minutes. MCP-4 eluted at ~40% buffer B. Fractions corresponding to peaks on the chromatogram were collected and analyzed by SDS-PAGE to ascertain which peak represented human MCP-4. Once this was established, the sample was lyophilized, resuspended in factor Xa buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl₂, pH 8.0) containing 1 M Urea, and digested for 2 hours at room temperature with factor Xa (Boehringer Mannheim, Indianapolis, IN) at an enzyme/protein weight ratio of 1:10. The digested protein was repurified by reverse phase HPLC using the same conditions as above, lyophilized, and resuspended in H₂O. The concentration of purified MCP-4 protein was determined by comparing the optical density (OD) at 550 nm to a dilution series of bovine serum albumen, following addition of the BCA reagent (Pierce, Rockford, IL).

B. MCP-4 Expression in COS Cells

To express MCP-4 in COS cells, PCR primers were designed to amplify the coding region of human MCP-4 plus a 30 nucleotide sequence encoding a 2 amino acid spacer followed by the 10 amino acid FLAG epitope (GSDYKDDDDK; SEQ ID NO:30). The 30 nucleotide extension was located immediately upstream from the MCP-4 stop codon. The resulting PCR product was subcloned into the pCDNA1/Amp^R vector, sequenced, and transfected into COS cells using DEAE-dextran, according to standard methods. Following transfection, cells were maintained in DMEM supplemented with 1% FCS for four days, after which time the supernatant was harvested and centrifuged at 1,000 x g for 15 minutes. MCP-4-FLAG was purified from the supernatant by affinity chromatography using an anti-FLAG monoclonal antibody (M2) column (Eastman Kodak Co., New Haven, CT) at 4°C. After washing the column with TBS (50 mM Tris-HCl, 15 mM NaCl, pH 7.4) the recombinant MCP4-FLAG protein was eluted with 0.1 M glycine hydrochloride, pH 3.5 and immediately neutralized with 1 M Tris, pH 8.0. The eluted protein was concentrated by ultrafiltration using Centricon 3 (Amicon, Danvers, MA) and dialyzed into phosphate buffered saline, pH 7.4. Recovered protein was quantified using the BCA Protein Assay Reagent (Pierce, Rockford, IL), and approximately 100 ng of

-33-

protein was electrophoresed into a Tris/Tricine 12.5% SDS-polyacrylamide gel under reducing conditions. The gel was electrotransferred onto a PVDF membrane (Dupont, Boston, MA) and analyzed by Western blotting using an anti-FLAG M2 monoclonal antibody followed by a horseradish peroxidase-conjugated sheep anti-mouse antibody (Kirkegard & Perry, Gaithersburg, MD) and developed by chemiluminescence (Dupont, Boston, MA).

The MCP-4 cDNA was engineered into the pCDNA-I/Amp expression vector, which bears a C-terminal FLAG tag, and used to transiently transfect COS cells. The supernatant of these cells provided a source of MCP-4 protein that was produced and processed by eukaryotic cells. The FLAG epitope was used to detect and purify MCP-4 from the COS cell supernatant (Fig 7A, lane 4). MCP-4 was expressed in *coli* as a fusion protein containing an N-terminal histidine tag separated from the predicted mature N-terminal Gln of MCP-4 by a factor Xa consensus site. This strategy was employed to generate MCP-4 protein with the predicted mature N-terminus; the presence of an unmodified amino-terminal amino acid is critical for the biological activity of MCP-1 and eotaxin. Following nickel affinity chromatography and reverse phase HPLC chromatography, the purified MCP-4 protein (with the tag) migrated as a doublet with an apparent Mr of ~10-12 kDa when electrophoresed in a denaturing polyacrylamide gel (Fig 7A, lane 1). This material exhibited no activity in an assay for monocyte chemotaxis (Fig. 7B), even at 1000 ng/ml. Therefore, the purified histidine tagged-MCP-4 protein was subjected to factor Xa digestion. Analysis by SDS-PAGE of the factor Xa digested (his)6-tagged MCP-4 protein revealed that the doublet had been converted to a smaller doublet migrating at ~8-9 kDa. This change in size is consistent with removal of the six N-terminal histidines. Two additional digestion products were also seen migrating at ~6 kDa and ~4 kDa. The factor Xa digested MCP-4 protein was repurified by reverse phase HPLC and tested on elutriated peripheral blood monocytes. The uncut MCP-4 protein had no chemotactic activity, while the factor Xa cut MCP-4 protein exhibited potent and dose-dependent monocyte chemotactic activity (Fig 7B). Due to the fact that additional cleavage of MCP-4 by factor Xa could not be suppressed, subsequent experiments (presented in the Examples below) utilized MCP-4 produced by PeproTech (Rocky Hill, NJ). Sequence analysis confirmed that this material was a single molecular species

-34-

containing the mature N-terminal Gln. However, in the Tris/Tris SDS-PAGE gel system, this material also migrated as a doublet at ~8 kDa with a dimer apparent at ~16 kDa (Fig. 7A, lane 2).

Translation of human MCP-4, beginning with the putative N-terminal Gln residue, predicts an 8,599 Da protein. MCP-4 produced by *E. coli* migrates at ~8 kDa on a 12.5% Tris/Tricine SDS-polyacrylamide gel, while MCP-4-FLAG migrates at ~9 kDa. MCP-4 has no consensus sites for N-linked glycosylation, but it may contain O-linked carbohydrates and sialic residues. However, since the MCP-4-FLAG contains 10 more amino acids at the carboxy terminus than the MCP-4 produced by *E. coli*, it is likely that MCP-4 is not heavily glycosylated, and may not be glycosylated at all. In addition, MCP-4 seems to aggregate, as evidenced by the dimer that appears on the Coomassie stained gel.

Example 7: Induction of Chemotaxis

A. MCP-4 Induced Monocyte and Eosinophil Chemotaxis

The chemotactic activity of the recombinant human MCP-4 protein was tested on primary human monocytes, neutrophils and eosinophils as follows. Fifty ml of replicate cells at 2×10^6 cells/ml for eosinophils, 1.0×10^6 cells/ml for neutrophils, and 5×10^6 cells/ml for mononuclear cells and monocytes in HBSS buffer (MediaTech) supplemented with 0.05% low endotoxin BSA (Sigma Chemical Co., St Louis, MO), were placed in the top wells of a 48 well micro-chemotaxis chamber (NeuroProbe, Inc., Cabin John, MD; Falk et al., J. Immunol. Methods 33:239-247, 1980). A standard 5- μ m pore polycarbonate filter (eosinophils and monocytes) and a polyvinylpyrrolidone-free 3- μ m pore polycarbonate filter (neutrophils) separated the cells from buffer alone (30 ml), buffer containing recombinant chemokines, or affinity purified FLAG-tagged MCP-4 protein. Cells were incubated at 37°C (60 minutes for eosinophils, 30 minutes for neutrophils, and 90 minutes for mononuclear cells and monocytes). The cells that migrated across the filter and adhered to the bottom side were stained with Diff-Quick (Baxter Scientific, McGaw Park, IL), and the number of cells per 400X field were counted.

MCP-4 exhibited chemotactic activity at concentrations comparable to other chemotactic MCPs, and this activity was as robust as the peak chemotactic responses

-35-

elicited by these MCPs. However, the other MCPs did begin to exhibit a reproducible chemotactic response at ~5-10 ng/ml, while 50 ng/ml of MCP-4 was required to detect a consistent chemotactic response, and the peak MCP-4 effect was seen at 100-1000 ng/ml. This response was observed for both purified monocytes (Fig. 8) and monocytes recruited from a mononuclear cell preparation (Fig. 9A). MCP-4 was also chemotactic for human peripheral blood eosinophils in a dose-dependent manner (Fig. 9B). There was variability in the magnitude of the eosinophil chemotactic response from donor to donor when compared to eotaxin, and variability in the dose-response, but purified eosinophils from all donors tested (n=5) responded to MCP-4. In contrast, recombinant MCP-4 did not elicit chemotaxis from human neutrophils, which responded strongly to IL-8 (Fig. 9C). Recombinant MCP-4 FLAG protein was also chemotactic for human peripheral blood monocytes and eosinophils, but not neutrophils. Therefore, potential post-translational modifications of MCP-4 and the carboxy-terminal FLAG epitope do not significantly affect the chemotactic activity of MCP-4.

B. MCP-5 Induction of Leukocyte Chemotaxis

Murine eosinophils, macrophages, and neutrophils and human mononuclear cells were suspended in HBSS with 0.05% BSA at 2.5, 5, 1, and 5 X 10⁶ cells/ml, respectively, and replicate cells were placed in the top well of a 48 well micro-chemotaxis chamber (Neuro Probe, Inc. Cabin John, MD). A polycarbonate filter with 5-μm pores (eosinophils, macrophages, and mononuclear cells) and a PVP-free filter with 3-μm pores (neutrophils) separated the cells from buffer alone or buffer containing purified recombinant murine eotaxin, human MCP-1, human IL-8 (PeproTech, Rocky Hill, NJ) or murine MIP1α, murine MIP-1β, murine JE, murine KC (R&D Systems, Minneapolis, MN). Murine MCP-5 was expressed and purified from *E. coli* by PeproTech, Inc. as the predicted mature 82 amino acid protein beginning with the N-terminal glycine. N-terminal sequence analysis of the purified recombinant MCP-5 preparation confirmed its homogeneity and the N-terminal glycine. Cells were incubated at 37°C for 30 minutes (neutrophils), 60 minutes (eosinophils) or 90 minutes (macrophages and mononuclear cells) and the cells that migrated across the filter and adhered to the bottom side of the filter were stained with Diff-Quick (Baxter Scientific, McGaw Park, IL).

-36-

The chemotactic activity of purified recombinant MCP-5 was evaluated on human peripheral blood monocytes, mouse thioglycolate elicited peritoneal macrophages, mouse eosinophils, and mouse neutrophils. MCP-5 was a potent chemoattractant for human peripheral blood monocytes as was mouse JE and human MCP-1 (Fig. 9D). MCP-5 had no activity on elicited mouse peritoneal macrophages, as was also absent for murine JE, although these macrophages did respond to murine MIP-1 α as a positive control (Fig. 9E). MCP-5 had minimal activity on murine eosinophils and only at doses 1000 ng/ml, while these cells were very responsive to the positive controls, eotaxin (peak chemotaxis at 50 ng/ml 94.5 nM) and MIP-1 α , and only minimally responsive to the negative controls, JE and MIP-1 β (Fig. 9F). Murine neutrophils exhibited no response to MCP-5 but responded strongly to the control agents, mouse KC and human IL-8 (Fig. 9G). These results demonstrate that purified MCP-5 is a potent dose-dependent chemotactic agent for peripheral blood monocytes.

Example 8: MCP-4 Induces the
Release of Histamine from Basophils

A. Purification of Monocytes,
Eosinophils and Neutrophils

Human mononuclear cells and granulocytes were obtained from whole peripheral blood of non-atopic and mildly atopic donors by passing the blood through a two step (1.077/1.119) Ficoll-Hypaque (Sigma Chemical Co., St. Louis, MO) density gradient. Monocytes were separated from the mononuclear cell layer by counter current flow elutriation using a JE-6 Beckman Centrifuge (Mason et al., Scand. J. Haematol, 34:5, 1985). The resulting monocyte fraction was estimated by examining Diff-Quick stained cytopsin preparations and found to be more than 90% pure. Contaminating cells were lymphocytes. Human eosinophils were purified from the granulocyte layer by negative selection with anti-CD16-coated immunomagnetic microbeads and the MACS magnet (Hansel et al., J. Immunol. Methods 145:105-110, 1991; Miltenyi Biotech, Auburn, CA). The resulting eosinophil purity was more than 90%, as determined by microscopic examination of Diff-Quick-stained cytopsin preparations. Contaminating cells were neutrophils.

-37-

B. Basophil Histamine Release Assays

Histamine release was determined by a modification of previously reported methods (Bischoff et al., J. Exp. Med., 172:1577-1582, 1990). The peripheral blood of mildly-atopic human donors was subjected to centrifugation over Ficoll-Paque (Pharmacia, Piscataway, NJ) and the top layer of cells was resuspended at 3×10^6 cells/ml in HA buffer (125 mM NaCl, 5 mM KCl, 1 mM $MgCl_2$, 1 mM $CaCl_2$, 0.5 mM glucose, and 0.025% BSA). Aliquots of the cells were warmed to 37°C, exposed to HA buffer alone, or to HA buffer containing either human IL-3 or human IL-5 (Genzyme) at 10 ng/ml for 10 minutes, and then challenged with recombinant human MCP-1, MCP-3, or MCP-4 (PeproTech Inc., Rocky Hill, NJ). After 20 minutes, the cells were centrifuged, and the supernatant was analyzed for histamine content by an enzyme-immunoassay (Immunotech, Westbrook, ME). Histamine release was expressed as the percentage of the total content of the sample (determined after cell lysis by sonication).

In order to determine whether MCP-4 is able to stimulate histamine release from basophils, histamine release was measured from basophils that were obtained from mildly atopic donors, either as freshly isolated or primed with IL-3. MCP-4 induced histamine release from primed basophils from 2 of the 4 donors tested (Table 4). MCP-3 had a similar effect in one of the MCP-4 responsive donor tested. In contrast, MCP-1 induced histamine release from IL-3-primed basophils from all four donors.

-38-

TABLE 4
Histamine Release (%)
Chemokine

	Cytokine	None	MCP 1	MCP 3	MCP4		
	10 ng/ml	-	500	500	100	250	500 (ng/ml)
1	0	3.5	1.0	4.2	ND	1.2	ND
	IL-3	3.6	29.0	8.0	ND	2.4	ND
2	0	4.2	2.9	2.0	ND	ND	0.2
	IL-3	4.1	77.0	41.0	ND	ND	88.0
3	0	22.0	27.0	ND	28.0	ND	50.0
	IL-3	36.0	87.0	ND	77.0	ND	83.0
4	0	0.1	0.2	ND	0.1	ND	0.2
	IL-3	0.1	26.0	ND	1.0	ND	4.0

Example 9: Analysis of Calcium Flux

A. Calcium Flux in Mononuclear Cells in Response to MCP-4

To determine whether MCP-4 induces a calcium flux in responding leukocytes, mononuclear cells were loaded with the calcium sensitive dye fura-2 and their response to human MCP-4 was monitored with a fluorimeter. Purified cells were loaded with 5.0 mM of the acetoxymethyl ester of fura-2 (fura-2 AM; Molecular Probes, Eugene, OR) for 60 minutes at 37°C in the dark at 1×10^7 /ml in DMEM supplemented with 1% heat-inactivated FBS. Loaded cells were washed twice and resuspended in a buffer containing 145 mM NaCl, 4 mM KCl, 1 mM NaHPO₄, 0.8 mM MgCl₂, 1.8 mM CaCl₂, 25 mM Hepes and 22 mM glucose. Two ml of cells (2×10^6 cells/ml) were placed in a continuously stirring cuvette at 37°C in a dual-wavelength excitation source fluorimeter (Photon Technology Inc, South Brunswick, NJ). Changes in the level of cytosolic free calcium were determined after addition of various human chemokines by monitoring the excitation fluorescence intensity emitted at 510 nm in response to sequential excitation at 340 nm and 380 nm. The data are presented as the relative ratio of fluorescence at 340 nm and 380 nm.

Concordant with the chemotaxis data presented above, MCP-4 induced a dose-dependent calcium flux in mononuclear cells (Fig. 10A), but not in neutrophils, even though the neutrophils responded appropriately to IL-8 (Fig. 10C). The half-maximal effective concentration of the MCP-4 induced monocyte calcium transient was ~35 nM, reaching saturation at ~125 nM (Fig. 10A). Rapid successive exposure to the same ligand is known to desensitize the signaling capacity of the G protein-linked receptors that are bound by chemokines. Likewise, exposure of cells to different ligands that utilize the same receptor can result in desensitization. Therefore, other chemokines, such as MCP-1, MCP-3, and RANTES, which are known to induce a calcium flux in human monocytes, were tested for the ability to cross-desensitize the MCP-4 signal. MCP-4 had no apparent effect on subsequent stimulation with either MCP-1 (Fig. 10A) or RANTES (Fig. 10B), even when a maximal initial MCP-4 stimulus was followed by a 20-fold lower MCP-1 stimulus. However, MCP-1 given first at 5 nM was able to completely desensitize the cells to a subsequent 100 nM MCP-4 stimulation (Fig. 10A). MCP-4 and MCP-3 were able to cross-desensitize each other in a dose-dependent manner (Fig. 10B), but MCP-4 and RANTES did not cross-desensitize each other (Fig. 10B).

B. Calcium Flux in Leukocytes in Response to MCP-5

Chemokines induce cell migration and activation by binding to specific G protein-coupled, seven transmembrane cell surface receptors on leukocytes. Signalling through these receptors results in a transient calcium flux. In order to determine whether MCP-5 induced a calcium flux in responding leukocytes, and thus examine the leukocyte specificity of MCP-5, purified subsets of leukocytes were loaded with the calcium sensitive dye fura 2, and their response to MCP-5 was monitored by fluorimetry.

Monocytes, macrophages, eosinophils and neutrophils were purified as follows. Peripheral blood mononuclear cells (PBMCs) were obtained from normal donors by density gradient centrifugation using 1.077 Histopaque™ (Sigma Chemical Co., St. Louis, MO). Murine eosinophils were isolated from the spleens of IL-5 transgenic mice by immuno-magnetic separation to remove the contaminating splenocytes, as described by Rothenberg et al., Mol. Med. 2:334-348, 1996). This process included subjecting splenocytes to hypotonic lysis in order to remove erythrocytes. The remaining leukocytes were labeled with anti-Thy-1 (M5/49), anti-B220 (6B2), or anti-Lyt-2 (53-6.7). The

antibody labeled cells were treated with sheep anti-rat serum coated-magnetic microbeads, and eosinophils were enriched by negative selection through a MACS magnet (Miltenyi Biotech., Auburn, CA). The purity of the eosinophils was greater than 90%, according to microscopic examination of Diff-Quick-stained (Baxter Scientific, McGaw Park, IL) cytopsin preparations. The contaminating cells were mononuclear. Macrophages were isolated from the peritoneal cavity of mice that had been treated 2 days prior with 1 ml of 2.5% Brewers thioglycollate (by intraperitoneal injection; Difco, Detroit, CA; Luo et al., J. Immunol. 153:4616-4624, 1994). Neutrophils were isolated from the peritoneal cavity of mice that had been treated either 4 or 18 hours previously with 1 mg of 9% sodium casein (by intraperitoneal injection; Sigma Chemical Co., St. Louis, MO). Macrophages and neutrophils were further purified by centrifugation in self-forming Percoll gradients. The resulting preparations were typically more than 90% pure.

Purified cells were loaded with 5.0 μ M of the acetoxymethyl ester of fura-2 (fura-2 AM; Molecular Probes, Eugene, OR) for 60 minutes at 37°C in the dark at 1×10^7 cells/ml in DMEM supplemented with 1% heat-inactivated FBS. Loaded cells were washed twice and resuspended in a buffer containing 145 mM NaCl, 4 mM KCl, 1 mM NaHPO_4 , 0.8 mM MgCl_2 , 1.8 mM CaCl_2 , 25 mM HEPES and 22 mM glucose. Two mls of cells (5×10^6 cells/ml) were placed in a continuously stirring cuvette at 37°C in a dual-wavelength excitation source fluorimeter (Photon Technology Inc., South Brunswick, NJ). Changes in cytosolic free calcium were determined after addition of the chemokines by monitoring the excitation fluorescence intensity emitted at 150 nm in response to sequential excitation at 340 nm and 380 nm. The data are presented as the relative ratio of fluorescence at 340 and 380 nm.

MCP-5 induced a dose-dependent calcium flux in mononuclear cells (Fig. 11C) but not in eosinophils, even at 50 μ g/ml or 5 μ M, or in neutrophils. As controls, the purified eosinophils responded appropriately to eotaxin and MIP-1 α (Fig. 11D) but did not respond to JE or MIP-1 β . Furthermore purified neutrophils responded appropriately to KC and IL-8 (Fig. 11E). The half-maximal effective concentration of the MCP-5-induced mononuclear cell calcium transient was approximately 7.5 ng/ml (75 nM) and reached saturation at approximately 500 ng/ml (50 nM; Fig. 11F). These results

demonstrate that MCP-5 induces a calcium flux in mononuclear cells, but not in eosinophils or neutrophils.

Example 10: Receptor Analysis

A. CKR2b and CKR3 are MCP-4 Receptors

5 To determine whether MCP-4 utilizes one of the known CC chemokine receptors, a panel of HEK-293 cell lines selected for stable expression of CKRs was used to test the ability of MCP-4 to induce a calcium transient (Fig. 11A). HEK293 cells were transfected with pREP9 expression plasmids encoding CC CKR2B, CC CKR3 and CC CKR5, and a pCEP4 expression plasmid encoding CC CKR1 as previously described.

10 Individual colonies resistant to G418 (1 mg/ml) or hygromycin (250 µg/ml) were selected and expanded. The derivation of these cell lines and their selectivity for CC chemokines other than MCP-4 have been previously reported. Cells were grown to confluence in DMEM with 10% FBS and G418 or hygromycin, harvested in PBS, loaded with 2.5 mM of fura-2 AM at 37°C for 45 minutes, and then washed twice in PBS. Cells (at 1 x 10⁶/ml

15 HBSS pH 7.4) were placed in a continuously stirred cuvette at 37°C in an MSIII fluorimeter (Photon Technology Inc., South Brunswick, NJ). Fluorescence was monitored at excitation frequencies of 340 nm and 380 nm, and emission frequencies of 510 nm. The data were collected every 200 msec, and presented as the relative ratio of fluorescence excited at 340 nm and 380 nm.

20 MCP-4 at 50 nM induced a calcium flux response in the CKR2B and CKR3 transfectants, but not in the CKR1 or CKR5 transfectants. The CKR1 cell line responded to MIP-1α, RANTES, and MCP-3, and the CKR5 cell line responded to MIP-1α, MIP-1β, and RANTES, confirming expression of the corresponding receptors in these MCP-4 unresponsive targets. Both the CKR2B and CKR3 cell lines responded to MCP-4

25 in a concentration-dependent manner with half-maximal effective concentrations of 15 and 20 nM, respectively, and reached saturation at 100 nM in each case (Fig. 11B). The EC₅₀ values are ~2-fold greater than those previously defined for eotaxin at CKR3 and for MCP-1 and MCP-3 at CKR2B using the calcium flux response in the same transfectants.

Cross-desensitization experiments were also performed on the CKR2b and CKR3

30 cell lines. As in mononuclear cells MCP-1 desensitized the MCP-4 response in the CKR2B cell line (Fig. 12A), although MCP-4 and MCP-3 did not extinguish the MCP-1

-42-

response. MCP-3 cross-desensitized the MCP-4 response but, in contrast to mononuclear cells, MCP-4 did not cross-desensitize the MCP-3 response. Using the CKR3 cell line (Fig. 12B) we were able to demonstrate that eotaxin and MCP-4 cross-desensitized each other using the same concentration of ligand. This discrepancy has been seen with other chemokine-induced calcium transients on leukocytes vs. a cell line-expressing a cloned chemokine receptor. The mechanism of homologous and heterologous desensitization for chemokine receptors may involve both physical sequestration as well as functional inactivation by phosphorylation. The ability of each chemokine to induce these processes could differ in different cell types, even for the same receptor, and could account for the asymmetric desensitization patterns observed in primary leukocytes and receptor transfectants.

B. CCR2 is an MCP-5 Receptor

Rapid and successive exposure to the same ligand desensitizes the signalling capacity of G protein-linked receptors. Likewise, exposure of cells to different ligands that utilize the same receptor signalling pathway can also result in desensitization. Therefore, the ability of other chemokines, such as mouse JE and human MCP-1, which are known to induce a calcium flux in human monocytes, were tested for their ability to cross-desensitize the MCP-5 signal. MCP-5 at 100 nM was able to completely desensitize the cells to subsequent stimulation with a 100 nM JE or human MCP-1 (Fig. 11C). This effect was dose-dependent. When the initial dose of MCP-5 was lowered to 1 nM, the mononuclear cells were no longer desensitized to subsequent stimulation with either 100 nM JE or MCP-1. In addition, 100 nM MCP-5 completely desensitized a subsequent cellular response to a 100 nM MCP-5 challenge. In contrast, mononuclear cells initially stimulated with 100 nM JE were not desensitized to a subsequent stimulation with 100 nM MCP-5 (Fig. 11C). Initial treatment of eosinophils and neutrophils with 100 nM MCP-5 had no effect on the ability of eosinophils to respond to 10 nM eotaxin or 10 mM MIP-1 α (Fig. 11D), or on the ability of neutrophils to respond to 10 nM KC (Fig. 11E). These results suggest that MCP-5 uses a receptor signalling pathway that is held in common by JE and MCP-1 and that is different from the receptor pathway utilized by MIP-1 α , MIP- β , eotaxin, and KC.

The studies of receptor desensitization described above suggested that MCP-5 shares a receptor with JE and MCP-1, and the signalling studies of eosinophils suggested that MCP-5 does not signal through the two receptors known to be expressed on eosinophils, CCR3 and CCR1. In order to directly test these suggestions, a panel of HEK-293 cell lines selected for stable expression of CCRs was used to examine the ability of MCP-5 to induce calcium flux.

HEK-293 cells stably expressing human CCR2b, CCR1, and CCR3, and murine CCR2 and CCR5 with the "FLAG" epitope at the extreme amino-terminus were prepared as described by Boring et al. (J. Biol. Chem. 271:7551-7558, 1996) and Montecarlo et al. (J. Biol. Chem. 271:19084-19092, 1996). The cells were grown in MEM with Eagle's salts supplemented with 10% fetal calf serum, 100 µg/ml penicillin, 100 µg/ml streptomycin, and 800 µg/ml G418 (Life Technologies Inc., Gaithersburg, MD). For calcium fluorimetry, cells were grown to log phase, loaded with the calcium-specific dye indo-1 AM (Molecular Probes, Eugene, OR), and assayed by spectrofluorimetry for changes in the concentration of intracellular calcium in response to addition of chemokines.

MCP-5 (100 nM) reproducibly induced a robust intracellular calcium flux in cells expressing CCR2 (Fig. 12B) but not CCR1, CCR3, or CCR5. In control experiments, functional expression of the cloned receptors in these MCP-5 unresponsive targets was confirmed: the CCR1- and CCR5-expressing cell lines responded to MIP-1α, and the CCR3-expressing line responded to eotaxin. Dose-response experiments demonstrated that MCP-5 was an excellent ligand for human CCR2b ($EC_{50} \leq 5$ nM) as was MCP-1, and both were more potent ligands than JE (Fig. 12B (i)). Since the MCP-5 described herein is a murine protein, it was compared directly to JE for activation of the murine MCP-1 receptor, CCR2. As shown in Fig. 12B (ii), JE induced a more robust intracellular calcium flux than MCP-5 in HEK-293 cells stably expressing murine CCR2.

Desensitization studies using cells transfected with human CCR2b revealed that MCP-5 blocked subsequent responses to MCP-5, MCP-1, and JE (Fig. 12C). Similar results were obtained when the initial agonist was MCP-1 or JE (Fig. 12C). However, MCP-1 did not completely desensitize the CCR2b transfectants to subsequent MCP-5 stimulation (Fig. 12C). These data are consistent with the desensitization responses

observed on human PBMCs, and with the hypothesis that MCP-5 is a full agonist for the human MCP-1 receptor (CCR2b).

Other Embodiments

5 The studies described herein, in which the novel chemokines MCP-4 and MCP-5 were discovered and characterized, provide the means to control the movement of inflammatory cells and, thereby, alter the immune response. For example, selectively suppressing these chemokines can be used to suppress the immune response in the event of an inflammatory condition such as asthma, atherosclerosis, arthritis, adult respiratory
10 distress syndrome, multiple sclerosis, and glomerulonephritis. In addition, administration of MCP-4 or MCP-5, or the receptor binding domains of these proteins, may prevent infection from pathogens that utilize chemokine receptors to enter the cell. For example, the human immunodeficiency virus (HIV) is thought to be an infectious agent that uses the chemokine receptor binding mechanism. Therefore, blocking receptor binding could
15 prevent viral entry into the cell. Conversely, administering MCP-4 or MCP-5 may enhance the immune response, e.g., in the event of an infection or tumor.

MCP-4 and MCP-5 Protein Expression

 In general, the polypeptides of the invention, MCP-4 and MCP-5, can be produced by transforming suitable host cells with all or part of the corresponding cDNA in a
20 suitable expression vehicle. Those skilled in the art of molecular biology will understand that any of a wide variety of expression systems may be used to provide the recombinant polypeptide. The precise host cell used is not critical to the invention. MCP-4 or MCP-5 polypeptides may be produced in a prokaryotic host, such as the bacterium *E. coli*, or in a eukaryotic host, such as an insect cell (e.g., Sf21 cells), or a mammalian cells (e.g., COS
25 cells, NIH 3T3 cells, or HeLa cells). These cells are available from many sources, including the American Type Culture Collection (Rockville, MD; see also Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1994). For a detailed description of the production of MCP-4 by *E. coli*, see Example 6 above.

 The method of transduction and the expression vehicle will depend on the host
30 system selected. Transduction methods are described by Ausubel et al. (*supra*), and

-45-

expression vehicles may be chosen from those widely known, such as those described in Cloning Vectors: A Laboratory Manual (P.H. Pouwels et al., 1985, Supp. 1987).

A preferred expression system is the baculovirus system, in which the expression vector pBacPAK9 (Clontech, Palo Alto, CA) is frequently used. If desired, this system may be used in conjunction with other protein expression techniques, for example, the myc tag technique described by Evan et al., (Mol. Cell. Biol. 5:3610-3616, 1985).

Alternatively, MCP-4 or MCP-5 may be produced by stably-transfected mammalian cell lines. Numerous vectors suitable for stable transfection of mammalian cells are available to the public (see Pouwels et al., *supra*). Methods for constructing stably-transfected mammalian cell lines are also publically available (e.g., in Ausubel et al., *supra*).

In addition to the example provided above, cDNA encoding all or part of the MCP-4 or MCP-5 polypeptide can be cloned into an expression vector, such as pCVSEII-DHFR or pAdD26SV(A), which includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid containing the MCP-4- or MCP-5-encoding gene into the host cell chromosome is selected for by inclusion of 0.01-300 μ M methotrexate in the cell culture medium (as described in Ausubel et al., *supra*). This type of selection can be accomplished in most cell types. Preferably, the cells will be DHFR-deficient, such as CHO DHFR⁻ cells (A.T.C.C. Accession No. CRL 9096). Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene. Methods for selecting cell lines bearing gene amplifications, which generally involve extended cell culture in medium containing increasing levels of methotrexate, are described in Ausubel et al. (*supra*).

Alternatively, the proteins of the invention, particularly fragments thereof, can be produced by chemical synthesis (e.g., using the methods described in Solid Phase Peptide Synthesis, Second Edition, The Pierce Chemical Company, Rockford, IL, 1984).

Once the recombinant MCP-4 or MCP-5 proteins are expressed, they can be isolated by standard biochemical techniques, such as affinity chromatography, and purified further, e.g., by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques in Biochemistry and Molecular Biology, Eds., Work and Burdon, Elsevier, 1980).

-46-

As described above, MCP-4 has an N-terminal glutamine residuc, as does MCP-1, MCP-2, and MCP-3. The biological activity of the expressed polypeptide may be substantially reduced either by addition of one or more amino acids prior to the N-terminal glutamine, or the deletion of one or more N-terminal residues. Addition of such amino acids may be particularly desirable for generating antiviral and anti-inflammatory polypeptide compounds. Such mutants may be produced by standard methods of genetic engineering and used to suppress the immune response or block pathogen entry via chemokine receptors. It is likely that, when administered in excess, the N-terminal mutant MCP-4 or MCP-5 polypeptide will suppress the immune response by effectively competing for the limited number of cell surface receptors, thereby blocking the response of these cells to the wild-type chemokine signals. As discussed below, the gene encoding such mutant polypeptides can also be administered.

Generation of Anti-MCP-4 or Anti-MCP-5 Antibodies

In order to generate MCP-4 or MCP-5-specific antibodies, the full-length MCP-4 or MCP-5 coding sequences or portions thereof can be expressed as C-terminal fusion molecules with glutathione S-transferase (GST; Smith et al., Gene 67:31-40, 1988). The coding sequence may encode either the full-length proteins, or fragments of these proteins that are likely to be antigenic, such as fragments that lie outside highly conserved regions or that contain a high proportion of charged residues. The fusion protein, which should conform to a predicted size, can then be purified with glutathione-Sepharose beads, eluted with glutathione, cleaved with thrombin (at an engineered cleavage site), and purified to the degree necessary for immunization of rabbits. Primary immunizations are typically carried out the Freund's complete adjuvant and subsequent immunizations with Freund's incomplete adjuvant. Antibody titres are monitored by Western blot and immunoprecipitation analyses using the thrombin-cleaved MCP-4 or MCP-5 protein fragment of the GST-MCP-4 or GST-MCP-5 fusion protein. Immune sera are affinity purified using CNBr-Sepharose-coupled MCP-4 or MCP-5 proteins. The specificity of the antiserum can be determined using a panel of unrelated GST fusion proteins (such as GST-p53, and GST-Rb) and GST-trypsin (which may be generated by PCR using published sequences).

-47-

As an alternate or adjunct immunogen, peptides corresponding to relatively unique regions of MCP-4 or MCP-5 (i.e. peptides that can be used to generate antibodies that specifically bind MCP-4 or MCP-5) may be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine. Antiserum to each of these peptides is then similarly affinity purified on peptides conjugated to BSA, and specificity is tested by ELISA and Western blot analysis using peptide conjugates.

Alternatively, monoclonal antibodies may be prepared using the MCP-4 and MCP-5 proteins described herein and standard hybridoma technology (see, e.g., Kohler et al., *Nature* 256:495, 1975; Kohler et al., *Eur. J. Immunol.* 6:511, 1976; Kohler et al., *Eur. J. Immunol.* 6:292, 1976; Hammerline et al., *In Monoclonal Antibodies and T Cell Hybridomas*, Elsevier, New York, NY, 1981). Once produced, monoclonal antibodies can be tested for their ability to specifically bind MCP-4 or MCP-5, as appropriate, by Western blot or immunoprecipitation analyses. Antibodies that specifically recognize MCP-4 or MCP-5 are considered useful in the invention; antibodies that can block the activity of MCP-4 or MCP-5 would be useful as agents to specifically block the accumulation of leukocytes (particularly monocytes) in unwanted instances of inflammation.

Generation of Transgenic Animals

Methods for generating transgenic animals, which incorporate an exogenous DNA molecule into their genome and pass it to their offspring, are well known to skilled artisans. Typically, the exogenous DNA is introduced into single-celled embryos that are obtained by mating male and female mice from a defined inbred genetic background (Brinster et al., *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985). If the mating is successful, the female mouse is sacrificed and the fertilized eggs are removed from the reproductive system. At this time, pronuclei are visible under the light microscope. Exogenous DNA, such as the MCP-4 or MCP-5 cDNA disclosed herein, is then introduced into the egg. Typically, the DNA is microinjected into a pronucleus, but other methods of transfection may also be used. A number of the microinjected eggs are then implanted into a pseudopregnant female mouse (pseudopregnancy is achieved by mating a normal female mouse with a vasectomized male mouse). These eggs will develop for the full period of gestation. The surrogate mother delivers the mice that develop from

these eggs, which are then tested (when they are approximately 4 weeks old) for the presence of the exogenous DNA.

Identification and Administration of Compounds
that Modulate Expression of MCP-4 and/or MCP-5

5 Isolation of the MCP-4 and MCP-5 cDNAs also facilitates the identification of molecules that increase or decrease the expression of these genes *in vivo*. Many quantitative assays for gene expression are known and may be utilized in this aspect of the invention. A few examples are provided below.

10 In order to identify molecules that modulate MCP-4 or MCP-5 gene expression, candidates are added at varying concentrations to the culture medium of cells expressing either MCP-4 or MCP-5 mRNA. MCP-4 or MCP-5 expression is then measured, for example, by Northern blot analysis using MCP-4 or MCP-5 cDNA hybridization probes. The level of MCP-4 or MCP-5 expression in the presence of the candidate molecule is compared with that measured in its absence.

15 Alternatively, the effect of the candidate molecule may be assessed at the level of translation by measuring the level of MCP-4 or MCP-5 protein, for example, by Western blot analysis or immunoprecipitation with an MCP-4 or MCP-5-specific antibody.

20 If the modulatory compound is an inhibitory compound, it may function by competing with MCP-4 or MCP-5 for the limited number of chemokine receptors on the cell surface. These compounds may be identified by, for example, examining the binding of MCP-4 or MCP-5 to their respective receptors in the presence and absence of the candidate compound. A compound that blocks chemokine receptors may be especially useful as an antiviral agent because some viruses, including the human immunodeficiency virus that causes AIDS, gain entry to the cell via chemokine receptors.

25 Candidate modulators may be purified, substantially purified, or may remain as one component of a mixture of compounds (e.g., as an extract or a supernatant obtained from a cell culture). In an assay of mixed compounds, MCP-4 or MCP-5 expression can be tested against progressively smaller subsets of the candidate compound pool. These subsets may be produced, e.g., by standard purification techniques such as HPLC or
30 FPLC, until a single compound or a minimal group of compounds is demonstrated to modulate the expression of MCP-4 and/or MCP-5.

Alternatively, or in addition, candidate modulatory compounds may be screened for those which modulate the chemotaxis of, e.g., monocytes, toward MCP-4 or MCP-5 producing cells. In this approach, chemotactic activity is simply compared in any standard assay of chemotaxis (including those described herein), under otherwise equivalent conditions, in the presence and absence of the candidate compound. Candidate modulatory compounds include peptide and non-peptide molecules, such as those found in cell extracts, mammalian serum, growth medium in which mammalian cells have been grown, or synthetic compounds. Particularly useful modulators of MCP-4 or MCP-5 expression include tumor necrosis factor- α , interleukin-1, interleukin-4, and interferon-gamma.

A molecule that decreases MCP-4 or MCP-5 expression or MCP-4 or MCP-5 chemotactic activity is considered particularly useful in the invention. This molecule may be used, for example, as a therapeutic to decrease the cellular levels of MCP-4 or MCP-5 expression, and thereby decrease the symptoms associated with MCP-4 or MCP-5 expression, including asthmatic reaction, chronic obstructive pulmonary diseases, bronchiectasis, cystic fibrosis, and inflammatory bowel diseases (i.e., Crohn's Disease and ulcerative colitis). Compounds that alleviate the inflammation associated with sinusitis are of particular interest. Infections, such as parasitic infections may also be treated with a molecule that inhibits MCP-4 or MCP-5 expression.

Conversely, a molecule that enhances MCP-4 or MCP-5 expression may be used in the treatment of cancer. As described below, enhanced leukocyte chemotaxis to the site of the tumor is desirable.

Modulatory compounds may be administered with a pharmaceutically-acceptable diluent, carrier, or excipient, according to conventional pharmaceutical practice. Any appropriate route of administration may be employed. For example, administration can be parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, transmucosal, or oral. The modulatory compound can be formulated in various ways, according to the corresponding route of administration. For example liquid solutions can be made for ingestion or injection; gels or powders can be made for ingestion, inhalation,

or topical application. Methods for making such formulations are well known and can be found in, for example, "Remington's Pharmaceutical Sciences."

MCP-4 or MCP-5-based Therapies

To enhance, for example, the infiltration of leukocytes into a tumor, a functional MCP-4 or MCP-5 gene or polypeptide may be administered to the patient.

Retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors with the appropriate tropism may be used as a gene transfer delivery system for a therapeutic cotaxin gene construct. Suitable vectors are generally known (see, e.g., Miller, Human Gene Therapy 15:14, 1990; Firedman, Science 244:1275-1281, 1989; Eglitis et al., BioTechniques 6:608-614, 1988; Tolstoshev et al., current Opinion in biotechnology 1:55-61, 1990). Retroviruses are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Patent No. 5,399,346).

Gene therapies that are not mediated by viral vectors may also be employed. For example, nucleic acid molecules encoding all or part of MCP-4 or MCP-5 may be encapsulated in liposomes and administered by lipofection (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neuroscience Lett. 117:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278, 1989; Staubinger and Papahadjopoulos, Meth. Enzymol. 101:512, 1983). Alternatively, the cells may be transfected by application of the nucleic acid molecules conjugated with asialorosonucoid-polylysine (Wu et al., J. Biol. Chem. 263:14621, 1988; Wu et al., J. Biol. Chem. 264:16985, 1989). Alternatively, MCP-4 or MCP-5 mRNA may be administered directly. The mRNA can be produced by any standard technique, but is most readily produced by *in vitro* transcription using an MCP-4 or MCP-5 cDNA under the control of a high efficiency promoter (e.g., the T7 promoter).

Preferably, the therapeutic MCP-4 or MCP-5 DNA construct is applied to the site of the malignancy or inflammation, to the tissue in the larger vicinity of a malignancy or inflammation, or to the blood vessels supplying these areas. The DNA construct administered may contain any suitable promoter, from which MCP-4 or MCP-5 gene expression is directed. Examples of such promoters include the human cytomegalovirus promoter, the simian virus 40 promoter, and the metallothionein promoter. Alternatively,

-51-

the promoter may be cell type-specific. For example, the tyrosine hydroxylase promoter may be used to direct gene expression within catecholinerbic neurons.

Ideally, the production of MCP-4 or MCP-5 by any gene therapy approach described herein will result in a cellular level of MCP-4 or MCP-5 expression that is at least equivalent to the normal, cellular level of expression of these genes. Skilled artisans will recognize that these therapies may be used in combination with more traditional therapies, such as surgery, radiotherapy, or chemotherapy.

Additional embodiments are within the following claims.

What is claimed is:

-52-

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: The General Hospital Corporation
- (ii) TITLE OF THE INVENTION: MCP-4 AND MCP-5: NOVEL CHEMOKINES
- (iii) NUMBER OF SEQUENCES: 30
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Clark & Elbing LLP
 - (B) STREET: 176 Federal Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02110
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 60/027,128
 - (B) FILING DATE: 30-SEP-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Bieker-Brady, Kristina
 - (B) REGISTRATION NUMBER: 39,109
 - (C) REFERENCE/DOCKET NUMBER: 00786/293WO2
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-428-0200
 - (B) TELEFAX: 617-428-7045
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 823 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

-53-

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AACATTGTGA	AATCTCCAAC	TCTTAACCTT	CAACATGAAA	GTCTCTGCAG	TGCTTCTGTG	60
CCTGCTGCTC	ATGACAGCAG	CTTTCAACCC	CCAGGGACTT	GCTCAGCCAG	ATGCACTCAA	120
CGTCCCATCT	ACTTGCTGCT	TCACATTTAG	CAGTAAGAAG	ATCTCCTTGC	AGAGGCTGAA	180
GAGCTATGTG	ATCACCACCA	GCAGGTGTCC	CCAGAAGGCT	GTCATCTTCA	GAACCAAACCT	240
GGGCAAGGAG	ATCTGTGCTG	ACCCAAAGGA	GAAGTGGGTC	CAGAATTATA	TGAAACACCT	300
GGGCCGGAAA	GCTCACACCC	TGAAGACTTG	AACTCTGCTA	CCCCTACTGA	AATCAAGCTG	360
GAGTACGTGA	AATGACTTTT	CCATTCTCCT	CTGGCCTCCT	CTTCTATGCT	TTGGAATACT	420
TCTACCATAA	TTTTCAAATA	GGATGCATTC	GGTTTTGTGA	TTCAAAATGT	ACTATGTGTT	480
AAGTAATATT	GGCTATTATT	TGACTTGTTG	CTGGTTTGGA	GTTTATTTGA	GTATTGCTGA	540
TCTTTTCTAA	AGCAAGGCCT	TGAGCAAGTA	GGTTGCTGTC	TCTAAGCCCC	CTTCCCTTCC	600
ACTATGAGCT	GCTGGCAGTG	GGTTGTATT	CGGTTCCCAG	GGGTTGAGAG	CATGCCTGTG	660
GGAGTCATGG	ACATGAAGGG	ATGCTGCAAT	GTAGGAAGGA	GAGCTCTTTG	TGAATGTGAG	720
GTGTTGCTAA	ATATGTTATT	GTGGAAAGAT	GAATGCAATA	GTAGGACTGC	TGACATTTTG	780
CAGAAAATAC	ATTTTATTTA	AAATCTCCTA	AAAAAAAAAA	AAA		823

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 98 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Lys	Val	Ser	Ala	Val	Leu	Leu	Cys	Leu	Leu	Leu	Met	Thr	Ala	Ala
1				5					10					15	
Phe	Asn	Pro	Gln	Gly	Leu	Ala	Gln	Pro	Asp	Ala	Leu	Asn	Val	Pro	Ser
			20					25					30		
Thr	Cys	Cys	Phe	Thr	Phe	Ser	Ser	Lys	Lys	Ile	Ser	Leu	Gln	Arg	Leu
		35					40					45			
Lys	Ser	Tyr	Val	Ile	Thr	Thr	Ser	Arg	Cys	Pro	Gln	Lys	Ala	Val	Ile
		50				55					60				
Phe	Arg	Thr	Lys	Leu	Gly	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Lys	Glu	Lys
65				70				75					80		
Trp	Val	Gln	Asn	Tyr	Met	Lys	His	Leu	Gly	Arg	Lys	Ala	His	Thr	Leu
			85					90					95		
Lys	Thr														

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 514 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

-54-

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

CTAGCTTTCA TTTGGAAGTC TTTGACCTCA ACATGAAGAT TTCCACACTT CTATGCCTCC    60
TGCTCATAGC TACCACCATC AGTCCTCAGG TATTGGCTGG ACCAGATGCG GTGAGCACCC    120
CAGTCACGTG CTGTTATAAT GTTGTTAAGC AGAAGATTCA CGTCCGGAAG CTGAAGAGCT    180
ACAGGAGAAT CACAAGCAGC CAGTGTCCCC GGAAGCTGT GATCTTCAGG ACCATACTGG    240
ATAAGGAGAT CTGTGCTGAC CCCAAGGAGA AGTGGGTTAA GAATTCCATA AACCACCTGG    300
ATAAGACGTC TCAAACCTTC ATCCTTGAAC CTTCACTGTCT AGGCTGAGAG TTCCAAAAAC    360
TCTTACGTAT TTCCCCCTGA AGTTCCCCAC GGCAGTGTG ATATTATTAT TGATATCTAA    420
AAAGAGATGT TTTTAATAAT TTAAACAAAC TTGCTTAAAT AATATTTAAT GGTATTTAAG    480
TAATATTTGG GCCAATTAAA CCGAATCTAA TTTA                                514

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Lys Ile Ser Thr Leu Leu Cys Leu Leu Leu Ile Ala Thr Thr Ile
 1              5              10              15
Ser Pro Gln Val Leu Ala Gly Pro Asp Ala Val Ser Thr Pro Val Thr
              20              25              30
Cys Cys Tyr Asn Val Val Lys Gln Lys Ile His Val Arg Lys Leu Lys
              35              40              45
Ser Tyr Arg Arg Ile Thr Ser Ser Gln Cys Pro Arg Glu Ala Val Ile
              50              55              60
Phe Arg Thr Ile Leu Asp Lys Glu Ile Cys Ala Asp Pro Lys Glu Lys
65              70              75              80
Trp Val Lys Asn Ser Ile Asn His Leu Asp Lys Thr Ser Gln Thr Phe
              85              90              95
Ile Leu Glu Pro Ser Cys Leu Gly
              100

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 99 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Lys Val Ser Ala Ala Leu Leu Cys Leu Leu Leu Ile Ala Ala Thr
 1              5              10              15

```


-55-

```

Phe Ile Pro Gln Gly Leu Ala Gln Pro Asp Ala Ile Asn Ala Pro Val
      20              25              30
Thr Cys Cys Tyr Asn Phe Thr Asn Arg Lys Ile Ser Val Gln Arg Leu
      35              40              45
Ala Ser Tyr Arg Arg Ile Thr Ser Ser Lys Cys Pro Lys Glu Ala Val
      50              55              60
Ile Phe Lys Thr Ile Val Ala Lys Glu Ile Cys Ala Asp Pro Lys Gln
65              70              75              80
Lys Trp Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr Gln Thr
      85              90              95
Pro Lys Thr

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Ala Gln Pro Asp Ser Val Ser Ile Pro Ile Thr Cys Cys Phe Asn Val
 1              5              10              15
Ile Asn Arg Lys Ile Pro Ile Gln Arg Leu Glu Ser Tyr Thr Arg Ile
      20              25              30
Thr Asn Ile Gln Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Lys Arg
      35              40              45
Gly Lys Glu Val Cys Ala Asp Pro Lys Glu Arg Trp Val Arg Asp Ser
      50              55              60
Met Lys His Leu Asp Gln Ile Phe Gln Asn Leu Lys Pro
65              70              75

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 99 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Met Lys Ala Ser Ala Ala Leu Leu Cys Leu Leu Leu Thr Ala Ala Ala
 1              5              10              15
Phe Ser Pro Gln Gly Leu Ala Gln Pro Val Gly Ile Asn Thr Ser Thr
      20              25              30
Thr Cys Cys Tyr Arg Phe Ile Asn Lys Lys Ile Pro Lys Gln Arg Leu
      35              40              45
Glu Ser Tyr Arg Arg Thr Thr Ser Ser His Cys Pro Arg Glu Ala Val

```

-56-

```

      50              55              60
Ile Phe Lys Thr Lys Leu Asp Lys Glu Ile Cys Ala Asp Pro Thr Gln
65              70              75              80
Lys Trp Val Gln Asp Phe Met Lys His Leu Asp Lys Lys Thr Gln Thr
      85              90              95
Pro Lys Leu

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Met Lys Val Ser Ala Ala Leu Leu Trp Leu Leu Leu Ile Ala Ala Ala
 1              5              10              15
Phe Ser Pro Gln Gly Leu Ala Gly Pro Ala Ser Val Pro Thr Thr Cys
      20              25              30
Cys Phe Asn Leu Ala Asn Arg Lys Ile Pro Leu Gln Arg Leu Glu Ser
      35              40              45
Tyr Arg Arg Ile Thr Ser Gly Lys Cys Pro Gln Lys Ala Val Ile Phe
      50              55              60
Lys Thr Lys Leu Ala Lys Asp Ile Cys Ala Asp Pro Lys Lys Lys Trp
65              70              75              80
Val Gln Asp Ser Met Lys Tyr Leu Asp Gln Lys Ser Pro Thr Pro Lys
      85              90              95
Pro

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Met Gln Val Ser Thr Ala Ala Leu Ala Val Leu Leu Cys Thr Met Ala
 1              5              10              15
Leu Cys Asn Gln Val Leu Ser Ala Pro Leu Ala Ala Asp Thr Pro Thr
      20              25              30
Ala Cys Cys Phe Ser Tyr Thr Ser Arg Gln Ile Pro Gln Asn Phe Ile
      35              40              45
Ala Asp Tyr Phe Glu Thr Ser Ser Gln Cys Ser Lys Pro Ser Val Ile
      50              55              60

```

-57-

Phe Leu Thr Lys Arg Gly Arg Gln Val Cys Ala Asp Pro Ser Glu Glu
 65 70 75 80
 Trp Val Gln Lys Tyr Val Ser Asp Leu Glu Leu Ser Ala
 85 90

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 92 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Lys Leu Cys Val Thr Val Leu Ser Leu Leu Met Leu Val Ala Ala
 1 5 10 15
 Phe Cys Ser Pro Ala Leu Ser Ala Pro Met Gly Ser Asp Pro Pro Thr
 20 25 30
 Ala Cys Cys Phe Ser Tyr Thr Ala Arg Lys Leu Pro Arg Asn Phe Val
 35 40 45
 Val Asp Tyr Tyr Glu Thr Ser Ser Leu Cys Ser Gln Pro Ala Val Val
 50 55 60
 Phe Gln Thr Lys Arg Ser Lys Gln Val Cys Ala Asp Pro Ser Glu Ser
 65 70 75 80
 Trp Val Gln Glu Tyr Val Tyr Asp Leu Glu Leu Asn
 85 90

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 84 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Lys Val Ser Ala Ala Arg Leu Ala Val Ile Leu Ile Ala Thr Ala
 1 5 10 15
 Leu Cys Ala Pro Ala Ser Ala Ser Pro Tyr Ser Ser Asp Thr Thr Pro
 20 25 30
 Cys Cys Phe Ala Tyr Ile Ala Arg Pro Leu Pro Arg Ala His Ile Lys
 35 40 45
 Glu Tyr Phe Tyr Thr Ser Gly Lys Cys Ser Asn Pro Ala Val Val Phe
 50 55 60
 Val Thr Arg Lys Asn Arg Gln Val Cys Ala Asn Pro Glu Lys Lys Trp
 65 70 75 80
 Val Arg Met Ser

-58-

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 148 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Met Gln Val Pro Val Met Leu Leu Gly Leu Leu Phe Thr Val Ala Gly
 1           5           10           15
Trp Ser Ile His Val Leu Ala Gln Pro Asp Ala Val Asn Ala Pro Leu
      20           25           30
Thr Cys Cys Tyr Ser Phe Thr Ser Lys Met Ile Pro Met Ser Arg Leu
      35           40           45
Glu Ser Tyr Lys Arg Ile Thr Ser Ser Arg Cys Pro Lys Glu Ala Val
      50           55           60
Val Phe Val Thr Lys Leu Lys Arg Glu Val Cys Ala Asp Pro Lys Lys
      65           70           75           80
Glu Trp Val Gln Thr Tyr Ile Lys Asn Leu Asp Arg Asn Gln Met Arg
      85           90           95
Ser Glu Pro Thr Thr Leu Phe Lys Thr Ala Ser Ala Leu Arg Ser Ser
      100          105          110
Ala Pro Leu Asn Val Lys Leu Thr Arg Lys Ser Glu Ala Asn Ala Ser
      115          120          125
Thr Thr Phe Ser Thr Thr Thr Ser Ser Thr Ser Val Gly Val Thr Ser
      130          135          140
Val Thr Val Asn
145

```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

Met Arg Ile Ser Ala Thr Leu Leu Cys Leu Leu Leu Ile Ala Ala Ala
 1           5           10           15
Phe Ser Ile Gln Val Trp Ala Gln Pro Asp Gly Pro Asn Ala Ser Thr
      20           25           30
Cys Cys Tyr Val Lys Lys Gln Lys Ile Pro Lys Arg Asn Leu Lys Ser
      35           40           45
Tyr Arg Arg Ile Thr Ser Ser Arg Cys Pro Trp Glu Ala Val Ile Phe
      50           55           60
Lys Thr Lys Lys Gly Met Glu Val Cys Ala Glu Ala His Gln Lys Trp

```

-59-

65		70		75		80									
Val	Glu	Glu	Ala	Ile	Ala	Tyr	Leu	Asp	Met	Lys	Thr	Pro	Thr	Pro	Lys
		85						90						95	
Pro															

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met	Gln	Ser	Ser	Thr	Ala	Leu	Leu	Phe	Leu	Leu	Leu	Thr	Val	Thr	Ser
1				5				10					15		
Phe	Thr	Ser	Gly	Val	Leu	Ala	His	Pro	Gly	Ser	Ile	Pro	Thr	Ser	Cys
			20					25					30		
Cys	Phe	Ile	Met	Thr	Ser	Lys	Lys	Ile	Pro	Asn	Thr	Leu	Leu	Lys	Ser
			35					40					45		
Tyr	Lys	Arg	Ile	Thr	Asn	Asn	Arg	Cys	Thr	Leu	Lys	Ala	Ile	Val	Phe
			50					55					60		
Lys	Thr	Arg	Leu	Gly	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Lys	Lys	Lys	Trp
			65					70					75		80
Val	Gln	Asp	Ala	Thr	Lys	His	Leu	Asp	Gln	Lys	Leu	Gln	Thr	Pro	Lys
			85					90						95	
Pro															

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 148 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met	Gln	Val	Pro	Val	Met	Leu	Leu	Gly	Leu	Leu	Phe	Thr	Val	Ala	Gly
1				5				10					15		
Trp	Ser	Ile	His	Val	Leu	Ala	Gln	Pro	Asp	Ala	Val	Asn	Ala	Pro	Leu
			20					25					30		
Thr	Cys	Cys	Tyr	Ser	Phe	Thr	Ser	Lys	Met	Ile	Pro	Met	Ser	Arg	Leu
			35					40					45		
Glu	Ser	Tyr	Lys	Arg	Ile	Thr	Ser	Ser	Arg	Cys	Pro	Lys	Glu	Ala	Val
			50					55					60		
Val	Phe	Val	Thr	Lys	Leu	Lys	Arg	Glu	Val	Cys	Ala	Asp	Pro	Lys	Lys
			65					70					75		80

-60-

Glu Trp Val Gln Thr Tyr Ile Lys Asn Leu Asp Arg Asn Gln Met Arg
 85 90 95
 Ser Glu Pro Thr Thr Leu Phe Lys Thr Ala Ser Ala Leu Arg Ser Ser
 100 105 110
 Ala Pro Leu Asn Val Lys Leu Thr Arg Lys Ser Glu Ala Asn Ala Ser
 115 120 125
 Thr Thr Phe Ser Thr Thr Thr Ser Ser Thr Ser Val Gly Val Thr Ser
 130 135 140
 Val Thr Val Asn
 145

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Arg Ile Ser Ala Thr Leu Leu Cys Leu Leu Leu Ile Ala Ala Ala
 1 5 10 15
 Phe Ser Ile Gln Val Trp Ala Gln Pro Asp Gly Pro Asn Ala Ser Thr
 20 25 30
 Cys Cys Tyr Val Lys Lys Gln Lys Ile Pro Lys Arg Asn Leu Lys Ser
 35 40 45
 Tyr Arg Arg Ile Thr Ser Ser Arg Cys Pro Trp Glu Ala Val Ile Phe
 50 55 60
 Lys Thr Lys Lys Gly Met Glu Val Cys Ala Glu Ala His Gln Lys Trp
 65 70 75 80
 Val Glu Glu Ala Ile Ala Tyr Leu Asp Met Lys Thr Pro Thr Pro Lys
 85 90 95
 Pro

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CTTCTGKGYC TGCTGYTCA

19

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

-61-

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ACAGCYTTYT DGGGACA

17

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TGTCCCHRRR ARGCTGT

17

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GSKTCAGCRC AGAYYTC

17

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CTGGCTGCTT GTGATTCTCC TGT

23

(2) INFORMATION FOR SEQ ID NO:22:

-62-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CAGTCCTCAG GTATTGGCTG G

21

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AGCTTTCATT TCGAAGTCTT TG

22

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TAGATTCGGT TTAATTGGCC C

21

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TCAGCCAGAT GCACTCAACG

20

(2) INFORMATION FOR SEQ ID NO:26:

-63-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TGGAAAAGTC ATTTCACGTA

20

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TTACAGGTCA GGTCCCCTAC T

21

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CTCCTTATCC AGTATGGTCC TG

22

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 89 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Met	Arg	Gly	Ser	His	His	His	His	His	His	Ile	Glu	Gly	Arg	Gln	Pro
1				5						10				15	
Asp	Ala	Leu	Asn	Val	Pro	Ser	Thr	Cys	Cys	Phe	Thr	Phe	Ser	Ser	Lys

-64-

		20					25				30				
Lys	Ile	Ser	Leu	Gln	Arg	Leu	Lys	Ser	Tyr	Val	Ile	Thr	Thr	Ser	Arg
		35					40					45			
Cys	Pro	Gln	Lys	Ala	Val	Ile	Phe	Arg	Thr	Lys	Leu	Gly	Lys	Glu	Ile
	50					55					60				
Cys	Ala	Asp	Pro	Lys	Glu	Lys	Trp	Val	Gln	Asn	Tyr	Met	Lys	His	Leu
65					70					75					80
Gly	Arg	Lys	Ala	His	Thr	Leu	Lys	Thr							
					85										

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Gly	Ser	Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys
1				5					10

-65-

1. A substantially pure nucleic acid molecule encoding MCP-4, or degenerate variants thereof.

2. The nucleic acid molecule of claim 1, wherein said MCP-4 is mammalian MCP-4.

3. The nucleic acid molecule of claim 1, wherein said molecule is operably linked to a regulatory sequence comprising a promoter.

4. A vector comprising the nucleic acid molecule of claim 1.

5. A cell comprising the vector of claim 4.

6. A transgenic animal generated from the cell of claim 5.

7. A substantially pure antibody that specifically binds a polypeptide encoded by the nucleic acid of claim 1.

8. A substantially pure polypeptide encoded by the nucleic acid of claim 1.

9. A therapeutic composition comprising as an active ingredient the polypeptide of claim 8.

10. A method of stimulating local immune response in a mammal, said method comprising administering to said mammal the nucleic acid molecule of claim 1.

11. A method of stimulating local immune response in a mammal, said method comprising administering to said mammal the cell of claim 5.

12. A method of modulating local immune response in a mammal, said method comprising administering to said mammal an MCP-4 modulator.

13. A method of inhibiting a local immune response in a mammal, said method comprising administering to said mammal an antibody that specifically binds MCP-4.

14. A method of inhibiting a local immune response in a mammal, said method comprising administering to said mammal a nucleic acid molecule, said molecule (a) consisting of least 8 nucleotides, and (b) having a sequence which is the reverse and complement of the nucleic acid molecule of claim 1.

15. A method of inhibiting a local immune response in a mammal, said method comprising administering to said mammal a mutant MCP-4 polypeptide.

16. A method of identifying a compound that is a modulator of MCP-4 expression, said method comprising

- (a) obtaining a population of cells that express MCP-4;
- (b) contacting a subset of said population of cells with a candidate modulator; and
- (c) comparing the level of MCP-4 expression in said subset of cells with the level of MCP-4 expression in an equivalent number of cells from said population of cells, a difference in said level indicating the presence of a compound that modulates MCP-4 expression.

-67-

17. A method of treating a mammal that is suffering from an infectious disease, said method comprising administering to said mammal a polypeptide encoded by the nucleic acid molecule of claim 1.

5 18. A substantially pure nucleic acid molecule encoding MCP-5, or degenerate variants thereof.

19. The nucleic acid molecule of claim 18, wherein said MCP-5 is mammalian MCP-5.

10 20. The nucleic acid molecule of claim 18, wherein said molecule is operably linked to a regulatory sequence comprising a promoter.

21. A vector comprising the nucleic acid molecule of claim 18.

15 22. A cell comprising the vector of claim 21.

23. A transgenic animal generated from the cell of claim 22.

20 24. A substantially pure antibody that specifically binds a polypeptide encoded by the nucleic acid of claim 18.

25 25. A substantially pure polypeptide encoded by the nucleic acid of claim 18.

26. A therapeutic composition comprising as an active ingredient the polypeptide of claim 25.

27. A method of stimulating a local immune response in a mammal, said method comprising administering to said mammal the nucleic acid molecule of claim 18.

5 28. A method of stimulating a local immune response in a mammal, said method comprising administering to said mammal the cell of claim 22.

29. A method of modulating a local immune response in a mammal, said method comprising administering to said mammal an MCP-5 modulator.

10 30. A method of inhibiting a local immune response in a mammal, said method comprising administering to said mammal an antibody that specifically binds MCP-5.

15 31. A method of inhibiting a local immune response in a mammal, said method comprising administering to said mammal a nucleic acid molecule, the sequence of which is the reverse and complement of the nucleic acid molecule of claim 18.

20 32. A method of inhibiting a local immune response in a mammal, said method comprising administering to said mammal a mutant MCP-5 polypeptide.

-69-

33. A method of identifying a compound that is a modulator of MCP-5 expression, said method comprising

(a) obtaining a population of cells that express MCP-5;

(b) contacting a subset of said population of cells with a candidate modulator; and

(c) comparing the level of MCP-5 expression in said subset of cells with the level of MCP-5 expression in an equivalent number of cells from said population of cells, a difference in said level indicating the presence of a compound that modulates MCP-5 expression.

34. A method of treating a mammal that is suffering from an infectious disease, said method comprising administering to said mammal a polypeptide encoded by the nucleic acid molecule of claim 18.

Figure 1A

```

                                -23
                                Met Lys Val Ser Ala Val Leu
                                --- --- --- --- --- ---
aacattgtgaaatctccaactcttaaccttcaac ATG AAA GTC TCT GCA GTG CTT 55
                                ↓ +1
Leu Cys Leu Leu Leu Met Thr Ala Ala Phe Asn Pro Gln Gly Leu Ala Gln Pro
--- --- --- --- --- --- --- --- --- --- --- ---
CTG TGC CTG CTG CTC ATG ACA GCA GCT TTC AAC CCC CAG GGA CTT GCT CAG CCA 109

Asp Ala Leu Asn Val Pro Ser Thr Cys Cys Phe Thr Phe Ser Ser Lys Lys Ile
--- --- --- --- --- --- --- --- --- --- --- ---
GAT GCA CTC AAC GTC CCA TCT ACT TGC TGC TTC ACA TTT AGC AGT AAG AAG ATC 163

Ser Leu Gln Arg Leu Lys Ser Tyr Val Ile Thr Thr Ser Arg Cys Pro Gln Lys
--- --- --- --- --- --- --- --- --- --- --- ---
TCC TTG CAG AGG CTG AAG AGC TAT GTG ATC ACC ACC AGC AGG TGT CCC CAG AAG 217

Ala Val Ile Phe Arg Thr Lys Leu Gly Lys Glu Ile Cys Ala Asp Pro Lys Glu
--- --- --- --- --- --- --- --- --- --- --- ---
GCT GTC ATC TTC AGA ACC AAA CTG GGC AAG GAG ATC TGT GCT GAC CCA AAG GAG 271

Lys Trp Val Gln Asn Tyr Met Lys His Leu Gly Arg Lys Ala His Thr Leu Lys
--- --- --- --- --- --- --- --- --- --- --- ---
AAG TGG GTC CAG AAT TAT ATG AAA CAC CTG GGC CGG AAA GCT CAC ACC CTG AAG 325
+75
Thr ***
--- ---
ACT TGA actctgctacccctactgaaatcaagctggagtacgtgaaatgacttttccattctcctctg 393
gcctcctctctctatgcttttgaatacttctaccataattttcaaataaggatgcattcgggtttgtgattca
aaatgtactatgtgttaagtaatatggctattatttgacttgttgcgtggtttggagtattatttgagtatt 535
gctgatcttttctaaagcaaggccttgagcaagtaggttgctgtctctaaagcccccttcccttccactatg
agctgctggcagtggtttgtattcgggttcccaggggttgagagcatgcctgtgggagtcattggacatgaa 677
gggatgctgcaatgtaggaaggagagctctttgtgaatgtgaggtgttgcataaatatgttattgtggaaag
atgaatgcaatagtaggactgctgacattttgcagaaaatacattttatttgaatctcctaaaaaaaaa 819
aaaa

```


	-32	
	Met Lys Ile Ser Thr Leu Leu Cys	
	--- --- --- --- --- --- ---	
caagcttcccttttcgaagtcttttgacccaac	Arg Arg Met Trp Asn Gln Tyr Cys Trp	56
Leu Leu Leu Ile Ala Thr Thr Ile Ser Pro Gln Val Leu Ala ⁺¹ Gly	Pro Asp Ala	
CCT CCT CCT AAA GGT ACT ACT ACC ACT GGT CAG GGA TGG GCT CGA CCA GAT CCG		110
Val Ser Thr Pro Val Thr Cys Cys Tyr Asn Val Val Lys Gln Lys Ile His Val		
CTC ACC ACC CCA GTC AGG TCC TGT TGT AAT GTT GTT AAG CAG AAG ATT CAC GTC		164
Arg Tyr Leu Lys Ser Thr Arg Arg Ile Thr Ser Ser Gln Cys Pro Arg Glu Ala		
TGG AAG CTC AAG ACC TAC AGC AAA ATC ACA ACC ACC CAG TGT CCC CCG GAA GCT		208
Val ⁺ Ile Phe Arg Thr Ile Leu Asp Lys Glu Ile Cys Ala Asp Pro Lys Glu Lys		
GTG ACC TTC AGC ACC AAA CTC GAT AAG GAG ATC TGT GCT GAC CCC AAG GAG AAG		272
Trp Val Lys Asn Ser Ile Asn His Leu Asp Lys Thr Ser Gln Thr Phe Ile Leu		
TGG GGT AAG ACT TCC AAA AAC CAC TTG GAT AAG ACC TCT CAA ACC TTC ATC CTY		326
	+32	
Glu Pro Ser Cys Leu Gly ---		

GAA CTC TCA TGT CAA GGC TGA gactcctaacaattctacctatctcccccgagaaccccac		390
gggaaayywwy-aa-ttgtgtgcagcatctcaaacagagatgttttatataaggagacacactgtcttaata		
atatcttagcgttacatttgataatcttggggccagcaggccgaabctaatctt(a) 72		510

Figure 2A

		+1		+75
		↓		
Hu MCP4	MKVSAVLLCLLLMTAAFNPOGLAQPDALNVPSTCCFTFSSKKISLQRLKSVYVITTSR-CPQKAVIFRTKLGKEICADPKEKWQNYMKHLGRKAUTLKT			
Hu MCP1	MKVSAALLCLLLIAATFIPOGLAQPDALNAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWQDSMDIILDQQTQTPKT			
Hu MCP2	-----AQPDSVSIPIITCCFNVINRKIPQRLSYTRITNIQCPKEAVIFKTRGKEVCADPKERWVRDMSKHLDDQIFQNLKP			
Hu MCP3	MKASAAALLCLLLTAAAFSPQGLAQPVGINSTTCCYRFINKKIPKQRLSYRRTTSSHCPRKAVIFKTLDKKEICADPTQKWQDFMKHLDDKKTQTPKL			
Hu EOT	MKVSAALLWLLLIAAFSPQGLAGPASV--PTTCCFNLANRKIPQRLSYRRTITSGKCPQKAVIFKTKLADKIDICADPKKWQDSMKYLDQKSPTPKP			
Hu MIP1 alpha	MQVSTRAALAVLLCTMALCNQVLSAPLAADPTACCFSYTSRQIPQNFIADY-FETSSQCSKPSVIFLTRGRQVCADPSEEWQKYVSDLELSA			
Hu MIP1 beta	MKLCVTVLSLLMLVAAPCSAPLAPMGSDPPTACCFSYTARKLPNPFVVDY-YETSSLSQPAVVFQTKRSQVCADPSESQVQVYVYDLELN			
Hu RANTES	MKVSAARLAVILIAATALCAPASAPSYSSDTPP-CCFAYIARPLPRAHIKEY-FYTSKCSNPVAVFVTRKNRQVCANPEKKWVMS			
Mu MCP1	MQVPVMLLGLLFTVAGWSIHVLAQPDVAVNAPLTCCYSFTSKMIPMSRLESYKRITSSRCPEAVVFTKLREVCADPKKEWQTYIKNLDNRQMRSEP>>>			
Mu MCP3	MRISATLLCLLLIAAFSIQVWAQPDG-PNASTCCYVKK-QKIPKRNLSYRRITSSRCPEAVIFKTKGMEVCAEAHQKWVEALAYLDMKTPTPKP			
Mu EOT	MQSSTALLFLLLTVTSTSGVLAHPGSI--PTSCCFINTSKKIPNTLLKSYKRITNNRCTLKAIVFKTRLGKEICADPKKWQVDATKHLDDQKLQTPKP			

mMCP-5
 mJE
 mFIC
 mEotaxin
 hMCP-1
 hMCP-2
 hMCP-3
 hMCP-4
 hEotaxin

-23
 M K I S T - L L C L L L I A T T I S P O V L A G P D A V S T P V T
 M Q V P V M L L G L L L T V A G W S I H V L A Q P D A V N A P L T
 M R I S A T L L C L L L I A A A F S I Q V W A Q P D G P N A S - T
 M Q S S T A L L L L L L T V T S P T S Q V L A H P G S I - - P T S
 M K V S A A L L C L L L I A A T F I P O G L A Q P D A I N A P V T
 - - - - - - - - - - - - - - - A Q P D S V S I P I T
 M K A S A A L L C L L L T A A A F S P Q G L A Q P V G I N T S T T
 M K V S A V L L C L L L M T A A F N P Q G L A Q P D A L N V P S T
 M K V S A A L L L W L L L I A A A F S P O G L A G P A S V - - P T T

+10
 ↓ +1

+11
 C C Y N V V K Q K I H V R K L K S Y R R I T S S Q C P R E A V I F
 C C Y S P T S K M I P M S R L E S Y K R I T S S R C P K E A V V F
 C C Y - V K K Q K I P K R N L K S Y R R I T S S R C P W E A V I F
 C C F I M T S K K I P N T L L K S Y K R I T N N R C T L K A I V F
 C C Y N F T N R K I S V Q R L A S Y R R I T S S K C P K E A V I F
 C C F N V I N R K I P I Q R L E S Y T R I T N I Q C P K E A V I F
 C C Y R F I N K K I P K Q R L E S Y R R I T S S H C P R E A V I F
 C C F T F S S K K I S L Q R L K S Y - V I T T S R C P Q K A V I F
 C C F N L A N R K I P L O R L E S Y R R I T S G K C P Q K A V I F

+43
 +44
 R T I L D K E I C A D P K E K W V K N S I N H L D K T S Q T F I L
 V T K L K R E V C A D P K K E W V Q T Y I K N L D R N Q M R S E P
 K T K K G M E V C A E A H Q K W V E E A I A Y L D M K T P T P K P
 K T R L G K E I C A D P K K K W V Q D A T K H L D Q K L Q T P K P
 K T I V A K E I C A D P K Q K W V Q D S M D H L D K Q T Q T P K T
 K T K R G K E V C A D P K E R W V R D S M K H L D Q I F Q N L K P
 K T K L D K E I C A D P T Q K W V Q D F M K H L D K K T Q T P K L
 R T K L G K E I C A D P K E K W V Q N Y M K H L G R K A H T L K T
 K T K L A K D I C A D P K K K W V Q D S M K Y L D Q K S P T P K P

+78
 +77
 E P S C L G F
 T T L F K T A S A L R S S A P L N V K L T R K S E A N A S T T F S

+109
 +110
 T T T S S T S V G V T S V T V N

+125

mMCP-5
 mJE
 mFIC
 mEotaxin
 hMCP-1
 hMCP-2
 hMCP-3
 hMCP-4
 hEotaxin

5/32




Figure 3A

Figure 3B




Figure 3C




Figure 3E




Figure 3F






Figure 4 A




9/32

Figure 4B




10/32

Figure 4c



11/32

Figure 4D



12/32

Figure 5 A





Figure 5 B



13/32

Figure 5c




Figure 5d




Figure 6 A




Figure 6 B






Figure 6 C



15/32

Figure 7



16/32

Figure 8





Figure 9A

Monocytes



18/32

Figure 9B

Eosinophils




Figure 9c

Neutrophils




Figure 9D PBMC




Figure 9E Peritoneal Macrophages




Figure 9F Eosinophils





Figure 9G Neutrophils



Concentration (ng/ml)




Figure 10A



Figure 10B

22/32

Figure 11A




Figure 11A Continued





Figure 11B



25/32

11C PBMC

Figure 11D Eosinophils








Figure 11E Neutrophils



Time (seconds) →

26/32

Figure 11F



27/32

Figure 12A




Figure 12B




Figure 12c




Figure 13




Figure 14A





Figure 14B



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/17900

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/12; A61K 48/00

US CL : 435/69.3, 320.1; 514/44; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.3, 320.1; 514/44; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG (file=biochem) databases. Key words: MCP-4, nucleic, DNA, monocyte chemoattractant protein 4

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y | US 5,413,778 A (KUNKEL et al.) 09 May 1995, see entire document. | 1-4, 10 |
| Y | US 5,459,128 A (ROLLINS et al.) 17 October 1995, see entire document. | 1-4, 10 |
| Y | UGUCCIONI, M et al. Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J. Exp. Med. May 1996, Vol. 183, pages 2379-2384, see abstract. | 1-4, 10 |

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

31 DECEMBER 1997

Date of mailing of the international search report

06 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THOMAS CUNNINGHAM

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/17900**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-4 and 10

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/17900

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-4 and 10, drawn to nucleic acid products encoding MCP-4 and to methods of using such products.

Group II, claim(s) 5 and 11, drawn to cells comprising DNA encoding MCP-4 and to methods of using such cells.

Group III, claim(s) 6, drawn to transgenic animals comprising DNA encoding MCP-4.

Group IV, claim(s) 7, 12 (in part) and 13, drawn to antibodies that bind to MCP-4 and methods of using such antibodies.

Group V, claim(s) 8-9, 12 (in part) 15 and 17, drawn to MCP-4 polypeptides and compositions.

Group VI, claim(s) 14, drawn to methods of using antisense MCP nucleic acids products.

Group VII, claim(s) 16, drawn to methods of identifying MCP-4 modulators.

Group VIII, claim(s) 18-21 and 27, drawn to nucleic acid products encoding MCP-5 and to methods of using such products.

Group IX, claim(s) 22 and 28, drawn to cells comprising DNA encoding MCP-5 and to methods of using such cells.

Group X, claim(s) 23, drawn to transgenic animals comprising DNA encoding MCP-5.

Group XI, claim(s) 24, 29 and 30, drawn to antibodies that bind to MCP-5 and methods of using such antibodies.

Group XII, claim(s) 25-26, 29, 32 and 34, drawn to MCP-5 polypeptides and compositions.

Group XIII, claim(s) 31, drawn to methods of using antisense MCP-5 nucleic acids products.

Group XIV, claim(s) 33, drawn to methods of identifying MCP-5 modulators.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-XIV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I-VII are directed to MCP-4, which lacks the corresponding structural features of the MCP-5 encompassed by Groups VIII-XIV.

Groups I, II, III, IV, V, VI and VII lack corresponding technical features as they are directed to products or methods encompassing structurally different products: DNA, cells expressing MCP-4, transgenic animals, antibodies, polypeptides, antisense nucleic acids or to methods that lack corresponding technical steps, e.g. methods of treatment (Groups I-VI) vs. methods of identification (Group VII).

Groups VIII-XIV lack corresponding technical features as they are directed to products or methods encompassing structurally different products: DNA, cells expressing MCP-5, transgenic animals, antibodies, polypeptides, antisense nucleic acids or to methods that lack corresponding technical steps, e.g. methods of treatment (Groups VIII-XIII) vs. methods of identification (Group XIV).

36/40




Fig. 12B-2

37/40




Fig. 12C

SUBSTITUTE SHEET (RULE 26)

38/40




Fig. 13

39/40




Fig. 14A

40/40





Fig. 14B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/17900

| A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) : C12N 15/12; A61K 48/00
US CL : 435/69.3, 320.1; 514/44; 536/23.5
According to International Patent Classification (IPC) or to both national classification and IPC | | |
|---|--|---|
| B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/69.3, 320.1; 514/44; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, DIALOG (file=biochem) databases. Key words: MCP-4, nucleic, DNA, monocyte chemoattractant protein 4 | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Y | US 5,413,778 A (KUNKEL et al.) 09 May 1995, see entire document. | 1-4, 10 |
| Y | US 5,459,128 A (ROLLINS et al.) 17 October 1995, see entire document. | 1-4, 10 |
| Y | UGUCCIONI, M et al. Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J. Exp. Med. May 1996, Vol. 183, pages 2379-2384, see abstract. | 1-4, 10 |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | |
| *
"A" | Special categories of cited documents:
document defining the general state of the art which is not considered to be of particular relevance | "T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" | earlier document published on or after the international filing date | "X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" | document referring to an oral disclosure, use, exhibition or other means | "A"
document member of the same patent family |
| "P" | document published prior to the international filing date but later than the priority date claimed | |
| Date of the actual completion of the international search
31 DECEMBER 1997 | | Date of mailing of the international search report
06 FEB 1998 |
| Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230 | | Authorized officer 
THOMAS CUNNINGHAM
Telephone No. (703) 308-0196 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/17900

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-4 and 10

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/17900

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-4 and 10, drawn to nucleic acid products encoding MCP-4 and to methods of using such products.

Group II, claim(s) 5 and 11, drawn to cells comprising DNA encoding MCP-4 and to methods of using such cells.

Group III, claim(s) 6, drawn to transgenic animals comprising DNA encoding MCP-4.

Group IV, claim(s) 7, 12 (in part) and 13, drawn to antibodies that bind to MCP-4 and methods of using such antibodies.

Group V, claim(s) 8-9, 12 (in part) 15 and 17, drawn to MCP-4 polypeptides and compositions.

Group VI, claim(s) 14, drawn to methods of using antisense MCP nucleic acids products.

Group VII, claim(s) 16, drawn to methods of identifying MCP-4 modulators.

Group VIII, claim(s) 18-21 and 27, drawn to nucleic acid products encoding MCP-5 and to methods of using such products.

Group IX, claim(s) 22 and 28, drawn to cells comprising DNA encoding MCP-5 and to methods of using such cells.

Group X, claim(s) 23, drawn to transgenic animals comprising DNA encoding MCP-5.

Group XI, claim(s) 24, 29 and 30, drawn to antibodies that bind to MCP-5 and methods of using such antibodies.

Group XII, claim(s) 25-26, 29, 32 and 34, drawn to MCP-5 polypeptides and compositions.

Group XIII, claim(s) 31, drawn to methods of using antisense MCP-5 nucleic acids products.

Group XIV, claim(s) 33, drawn to methods of identifying MCP-5 modulators.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-XIV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I-VII are directed to MCP-4, which lacks the corresponding structural features of the MCP-5 encompassed by Groups VIII-XIV.

Groups I, II, III, IV, V, VI and VII lack corresponding technical features as they are directed to products or methods encompassing structurally different products: DNA, cells expressing MCP-4, transgenic animals, antibodies, polypeptides, antisense nucleic acids or to methods that lack corresponding technical steps, e.g. methods of treatment (Groups I-VI) vs. methods of identification (Group VII).

Groups VIII-XIV lack corresponding technical features as they are directed to products or methods encompassing structurally different products: DNA, cells expressing MCP-5, transgenic animals, antibodies, polypeptides, antisense nucleic acids or to methods that lack corresponding technical steps, e.g. methods of treatment (Groups VIII-XIII) vs. methods of identification (Group XIV).